Podcasts about T1

Join MonteCristo and Thorin as they rank discuss the start of the LEC and LCK regular seasons, the dominating debut of G2, Vitality living up to the early hype, how T1 and Dplus should vie for the title in Korea, the announced changes to the upcoming LCS broadcast, how most teams are playing through bot lane, and more.

Welcome back to another fantastic episode of the Just Spitballin Podcast! We didn't have too many topics but we have a Ichigo Vs Luffy Vs naruto convo with a twist! Then we do a new bracket with Forgotten cartoons! If you like what you hear be sure to Follow our social media: Facebook: Just lol Spitballin Ent. Twitch:JSE4GAMING. Twitter: @JSpitballin Instagram: justspitballin_ent YouTube: Just Spitballin Time stamps: T1: 1:33 naruto with all powers Vs Ichigo with all Bankais vs Luffy with all devil fruits. T2: 37:44 Forgotten Cartoon Network shows bracket --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.01.06.522927v1?rss=1 Authors: Murali-Manohar, S., Gudmundson, A. T., Hupfeld, K. E., Zöllner, H. J., Hui, S. C. N., Song, Y., Davies-Jenkins, C. W., Gong, T., Wang, G., Oeltzschner, G., Edden, R. A. E. Abstract: Purpose: To investigate the age-dependence of metabolite T1 relaxation times at 3T in both gray- and white-matter-rich voxels. Methods: This manuscript analyzes publicly available metabolite and metabolite-nulled (single inversion recovery TI = 600 ms) spectra acquired at 3T using PRESS localization. Voxels were placed in posterior cingulate cortex and centrum semiovale in 102 healthy volunteers across 5 decades of life (20s to 60s). All spectra were analyzed in Osprey v2.4.0. To estimate T1 relaxation times for tNAA2.0 and tCr3.0, the ratio of modeled metabolite residual amplitudes in the metabolite-nulled spectrum to the full metabolite signal was calculated using the single inversion recovery signal equation. Correlations between T1 and subject age were evaluated. Results: Spearman correlations revealed that estimated T1 relaxation times of tNAA2.0 (rs = -0.43; p less than 0.001) and tCr3.0 (rs = -0.23; p = 0.021) decreased significantly with age in white-matter-rich CSO, and less steeply (and not significantly) for tNAA2.0 (rs = -0.15; p = 0.136) and tCr3.0 (rs = -0.10; p = 0.319) in gray-matter-rich PCC. Conclusion: The analysis harnessed a large publicly available cross-sectional dataset to test an important hypothesis, that metabolite T1 relaxation times change with age. This preliminary study stresses the importance of further work to measure age-normed metabolite T1 relaxation times for accurate quantification of metabolite levels in studies of aging. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

1. Manchester United 1st Half ML vs. Everton -115 for 1.5 Units* Man United has been on a roll recently, ditching Ronaldo helped team morale, and get a home FA Cup game* Everton is scrambling after a mid-week drubbing 4-1 to Brighton on the road* I think the Red Devils score early, they slot home a 2nd possibly a 3rd in the 2nd half, & keep it moving in the FA Cup.2. Western Michigan Broncos vs. Toledo Rockets Under 157.5 -110 1 Unit* This under hinges on Western Michigan to me, they are 5-2 on road overs, but they only average just over 68 PPG* So unless Toledo scores 90+, which they average 84 PPG, then this one feels good.* The Broncos also only give up 69 PPG, so I think they do well here to keep it closer to 80 PPG.3. Calgary Flames In Regulation vs. New York Islanders -125 For 1.5 Units* Isles got slapped by Edmonton last night, but back-to-back road games are tough* Markstrom is 12-10-4 on the year and Varlamov is expected, even with his 8-3-1 record he's a backup* CAL are 11-7-2 at home this year, they will make it 12 wins after tonight4. Tampa Bay Lightning vs. Winnipeg Jets Under 6 -121 For 2 Units* Should be Vasilevsky and Hellebuyck who have both been great* The last six head-to-head goals had 7 or more goals, hitting double digits twice as well, but Winnipeg playing much better* Feels like eventually, both goalies have to play well in this H2H and this feels like the spot with 17 unders in the past 20.5. Sentry Tournament Of Champions Plays Update* 0.5 unit on Collin Morikawa's Top 10 at +124 is T1 after the first day.* Viktor Hovland at the same value is T8. NBAIndiana Pacers ML vs. Portland Trail Blazers -125 New York Knicks +3.5 vs. Toronto Raptors -110NHLWashington Capitals ML vs. Nashville Predators -155Drop A 5-Star Review & Follow Us On All Our Social Media PlatformsTwitter Facebook YoutubeAlso, Go & Check Out Our Phenomenal Sponsors Down Below!Sign Up For Bet99 HereCheck Out Last Mountain Distillery HereThanks for reading Competitive Hedge Show Plays! Subscribe for free to receive new posts and support my work. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit hedgepod.substack.com

202年最後一集啦↓↓↓ (01:49) 聖誕節活動! (07:18) Eric放棄Fantasy (18:19) 全明星投票 (23:44) 籃網開始往上 (28:28) Morant開炮~ (34:09) 推歌時間~ Tyga - Sheikh Talk、Meek Mill - God Did 別忘了小額贊助

Brett, Matt, Jason & Drew talk about their recent trip to South Korea and what the gaming scene is like there - from visiting retro game stores, electronic hubs, and eSports arenas like T1. --- Support this podcast: https://anchor.fm/dreblergaming/support

ALERTA SPOILERS Si es que las cosas que hacemos por amor. Nos hemos arriesgado a romper el tejido del universo viajando en el tiempo para poder traeros este especial en el que hablamos con detalles y MUCHOS SPOILERS, de la T1 de Star Wars: Andor, una serie que nos pusimos a ver sin demasiadas expectativas … Continuar leyendo "s17e06: (SPOILERS) Especial Andor"

A new research paper was published in Aging (listed as "Aging (Albany NY)" by MEDLINE/PubMed and "Aging-US" by Web of Science) Volume 14, Issue 23, entitled, “White matter hyperintensity load is associated with premature brain aging.” Brain age is an MRI-derived estimate of brain tissue loss that has a similar pattern to aging-related atrophy. White matter hyperintensities (WMHs) are neuroimaging markers of small vessel disease and may represent subtle signs of brain compromise. In this new study, researchers Natalie Busby, Sarah Newman-Norlund, Sara Sayers, Roger Newman-Norlund, Sarah Wilson, Samaneh Nemati, Chris Rorden, Janina Wilmskoetter, Nicholas Riccardi, Rebecca Roth, Julius Fridriksson, and Leonardo Bonilha from University of South Carolina, Medical University of South Carolina and Emory University tested the hypothesis that WMHs are independently associated with premature brain age in an original aging cohort. “We hypothesized that a higher WMH load is linearly associated with premature brain aging controlling for chronological age.” Brain age was calculated using machine-learning on whole-brain tissue estimates from T1-weighted images using the BrainAgeR analysis pipeline in 166 healthy adult participants. WMHs were manually delineated on FLAIR images. WMH load was defined as the cumulative volume of WMHs. A positive difference between estimated brain age and chronological age (BrainGAP) was used as a measure of premature brain aging. Then, partial Pearson correlations between BrainGAP and volume of WMHs were calculated (accounting for chronological age). Brain and chronological age were strongly correlated (r(163)=0.932, p

Enjoy this rare interview with our cross-country running, T1 phenomenon, Don Muchow! A lifelong advocate of immersive, dystopian SF, he believes that buried in the shadows of every dark future lies the inextinguishable spirit of hope and the yearning for a better tomorrow. When he's not imagining dystopian futures, you can catch Don running across the US or planning his next epic exploit. For more information, visit t1determined.org. Here are the books he mentions in this fun , interesting and thoughtful episode. 8:19 - Where Don grew up and his family life 10:25 - Don's educational background and his lifelong passion (it isn't what you might think!) 12:41 - What Don wanted to be when he grew up 14:43 - Who are the Scully and Mulder of Fiction? 16:30 - What aspect of writing is most intriguing to Don? 18:51 - Are any of the Untold Tales stories you've written TRUE or inspired by real life events? 24:58 - DNA Memory? An explanation as it relates to storytelling 25:38 - Kim Stanley Robinson https://www.amazon.com/Kim-Stanley-Robinson/e/B000APVJXC/ref=dp_byline_cont_pop_book_1 Red Mars, Blue Mars, Green Mars trilogy https://amzn.to/3Ntq9Vc 34:55 - Arrival by Ted Chiang https://amzn.to/3T0PCqm 35:30 - Banned Books List https://www.thefire.org/first-amendment-library/special-collections/banned-challenged-books/ 35:58 - What Don thinks about the Untold Tales Podcast (this is GOOD) --- Support this podcast: https://anchor.fm/untold-tales/support

2022 has been a year full of important news, events, changes, and more within the Telemark world. This week I go back over some of those important stories along with some of my favorite 2022 podcast episodes that you may want to check out.  New Freeheel Life Retail Hours 12-7 Monday, Wednesday, & Friday -  Saturday 10-4 Nicolas C. Osborn Obituary: https://tricornernews.com/obituaries/nicolas-c-osborn Crispi Kills the XP Scarpa puts T1 to rest.  SCOTT Kills their 75mm boots: Synergy and Voodoo  M-Equipment announced that it will now become INWILD  We got our first customers on the Freeheel Life Protectors! Here are couple reviews A NEW DOCUMENTARY called Telemarkeras was announced that will be coming out in 2023  Some of my favorite episodes I think you should check out:  #112 - Todd Stuart | Author of Nobody Owes You Tomorrow #116 - The Death of 75mm w/ Taylor Johnson #129 - Connie Marshall | Alta Legend & Telemark Skier #134 - The Road to a Single Norm — Telemark #139 - Art Burrows | Designer & Telemark Pioneer #145 - Message for The Beginner Telemark Skier   Sign-up for the mailing list: https://bit.ly/FHLMailingList Connect with Josh and the Freeheel Life Family  Josh on Instagram, Facebook, and Twitter  Telemark Skier Magazine on Instagram, Twitter and YouTube Freeheel Life on Instagram and Twitter Shop The Freeheel Life Telemark Shop  How You Can Support Us: Shop Telemark at  FREEHEELLIFE.COM Subscribe & Become a Supporter of TelemarkSkier.com for articles, gear reviews, & more! Email Podcast@freeheellife.com

This week, please join author Trisha Singh as she discusses her article "Manganese-Enhanced Magnetic Resonance Imaging in Takotsubo Syndrome." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass for the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Nam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Carolyn, very interesting feature discussion this week. Many times we hear in magnetic resonance imaging the use of gadolinium contrast. And remember, gadolinium is an extracellular agent. And when we apply it in the heart, we look for infarcts, or areas of the heart that are perhaps dead, or scarred over. This week's feature discusses manganese as a contrast agent and it is an intracellular contrast agent. And very interestingly, it identifies calcium handling, so it's a marker of viability. And these authors are going to apply manganese as well as gadolinium in trying to understand mechanisms behind Takotsubo cardiomyopathy. But before we get to that, how about we grab a cup of coffee and jump into some of the other articles in the issue? Dr. Carolyn Lam: Oh, I'd love to tell you about the other articles. But just have to first say, I loved your description of the feature paper. It's right up your alley and I can't wait to learn more. But my first paper today I want to talk about pulse field ablation. Now, what is that? Pulse field ablation, or PFA, is a unique and novel technique to treat atrial fibrillation. It has a unique safety profile largely related to its preferentially for myocardial tissue ablation. And thus, sparing the esophagus and thus, deemed to have a unique safety profile. Now, a pentaspline catheter was the first such PFA system studied for AF ablation. And in the initial trials the catheter was used for pulmonary vein isolation and left atrial posterior wall ablation. However, following its regulatory approval in Europe, in clinical practice, physicians have ablated both these locations and expanded lesions that could be in closer proximity to the coronary arteries. Now, this is an unstudied important issue since preclinical and maybe some clinical data have raised the potential for coronary arterial spasm. Hence, the investigators led by Dr. Vivek Reddy from Icahn School of Medicine at Mount Sinai and colleagues studied the vasal spastic potential of PFA lesion sets, both remote from and adjacent to coronary arteries. Dr. Greg Hundley: Wow, Carolyn, this is a really interesting question. So what did they find? Dr. Carolyn Lam: In this retrospective analysis of a series of 25 patients undergoing PFA for atrial fibrillation in whom coronary angiography was performed pre, during and post ablation, they found that during pulmonary vein isolation and left atrial posterior wall ablation, coronary spasm did not occur. However, cavotricuspid isthmus ablation provoked severe subtotal vasospasm in five out of five consecutive patients. And this was relieved by in coronary nitroglycerin. ST elevation was not observed. No patient had severe spasm if first pretreated with parenteral nitroglycerin, either intracoronary or intravenous. And so in summary, coronary vasospasm was not provoked during PFA at locations remote from the coronary arteries. But when the energy is delivered adjacent to a coronary artery, like in cavotricuspid isthmus ablation, PFA did provoke subclinical vasospasm. And the phenomenon was attenuated by nitroglycerine administered either post hoc to treat spasm or as prophylaxis. And this is discussed in accompanying editorial, I like it, “Coronary Vasospasm in PFA Primum Non Nocere” by Drs. Estes and Sundeep and Saba. Dr. Greg Hundley: Very nice Carolyn. Very important research in this area using that particular methodology. Well Carolyn, my next study comes to us again from preclinical science. And Carolyn, this study evaluated mechanisms responsible for pulmonary hypertension. So as background, pulmonary hypertension is associated with increased expression of VEGFA and it's receptor VEGFR-2. But whether and how activation of VEGFA signal participates in the pathogenesis of pulmonary hypertension, that's unclear. And so these authors led by Dr. Yangxin Chen from Sun Yat-Sen Memorial Hospital and Sun Yat-Sen University evaluated VEGFA, VEGFR-2 signal activation and VEGFR-2 Y949 dependent vascular leak in lung samples from patients with pulmonary hypertension as well as in mice exposed to hypoxia. Dr. Carolyn Lam: Another one of those excellent translational pieces, isn't it Greg? So what did they find? Dr. Greg Hundley: Right Carolyn. So these authors found that pulmonary hypertension led to excessive pulmonary vascular leak in both patients and hypoxic mice. And this was owing to over activated VEGFA and VEGFR-2 Y949 signaling axis. Abolishing VEGFR-2 Y949 signaling via a specific point mutation was sufficient to prevent pulmonary vascular permeability and inhibit macrophage infiltration and Rac1 activation in smooth muscle cells under hypoxia exposure. This, in turn, led to alleviation of pulmonary hypertension manifestations including muscularization of distal pulmonary arterials, elevation of right ventricular systolic pressure and right ventricular hypertrophy. And so Carolyn, in summary, these results suggest that VEGFA, VEGFR-2 Y949 dependent vascular permeability is an important determinant in the pathogenesis of pulmonary hypertension and might serve as an attractive therapeutic target pathway for this disease. Dr. Carolyn Lam: Aw, thanks Greg for explaining that so well. The next paper talks about transcatheter aortic valve replacement of TAVR, recognizing that it is a well established treatment now for high and intermediate risk patients with severe symptomatic aortic stenosis. However, the question asked here is what makes some, but not all patients improve their left ventricular ejection fraction following TAVR associated after load reduction? Now, hypothesizing that circulating microRNAs may play a role here, the authors led by corresponding authors, Dr. Hosen and Jansen from University of Bonn and their colleagues profiled the differential expression of microRNAs in circulating extracellular vesicles in patients after TAVR. And in particular, the novel role of circulating microRNA 1225p in cardiomyocytes. Dr. Greg Hundley: Oh wow. So Carolyn, important study. So what did they find? Dr. Carolyn Lam: Well, first aortic stenosis increases circulating microRNA 1225p, which correlated with a lack of improvement of the EF in patients after TAVR. Extracellular vesicles harbored microRNA 1225p and facilitated its startling into the cardiomyocytes. Vesicular shuttling of this particular microRNA was regulated by a direct interaction with a multifunctional RNA binding protein called heterogeneous nuclear ribonucleoprotein U in a sequence specific manner. Extracellular vesicles containing the specific microRNA post transcriptionally repressed BCL2 an anti-apoptotic gene, which is central to cell viability and apoptosis. So in summary, Greg, an increase in extracellular vesicle microRNA 1225p in patients with aortic stenosis represents a novel mechanism for the deterioration of cardiac function in patients following TAVR. And pharmacological manipulation of this axis may improve ejection fraction and cardiac function in patients with aortic stenosis by improving the viability of cardiomyocytes, which opens the door to a potential therapeutic approach in patients with limited EF improvement following TAVR. Dr. Greg Hundley: Oh Carolyn, beautiful, beautiful description of that wonderful preclinical science. Well, let's reach into the mail bag and see what else is in the issue. And first, there's a research letter by Professor van Raalte entitled “Kidney Hemodynamic Effects of Angiotensin Receptor Blockades Sodium Glucose Co-transporter 2 Inhibition Alone and in Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes.” And Carolyn, there's also an In Depth piece from Dr. Marx entitled “GLP1 Receptor Agonist for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes.” Dr. Carolyn Lam: Very, very nice papers, those two. There's also an exchange of letters between Drs. Hou and Sedej regarding the article, “Fine Tuning Cardiac Insulin Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity.” As well as a Perspective by Dr. Eagle, “Comments on the 2022 Aortic Guidelines: Seeking More Precision in Aortic Care.” Now, let's go onto the feature discussion of all things MRI, shall we? Dr. Greg Hundley: You bet. More on manganese. Welcome listeners to this very interesting feature discussion on December 13th. And we have with us Dr. Trisha Singh from the University of Edinburgh in Edinburgh, Scotland. Welcome, Trisha. This is a fascinating study incorporating manganese cardiovascular magnetic resonance to study some of the mechanistic underpinnings of hypokinesis left ventricular hypokinesis in patients with Takotsubo syndrome. So maybe just describe for us some of the background information that went into the preparation of your study, and what was the hypothesis that you wanted to address? Dr. Trisha Singh: Yes, of course. So we know with patients with Takotsubo syndrome, it predominantly affects middle aged women, patients present with a degree of left ventricular dysfunction, which is transient. And, unfortunately, it can be quite difficult to diagnose because it can phenotypically present very similar to an acute coronary syndrome. We know from previous studies that these patients do have ongoing symptoms despite normalization of their LV function. And actually their outcomes are not as benign as previously thought. In terms of manganese enhanced MRI imaging, we at Edinburgh University have imaged patients with other cardiac conditions such as hypertrophic cardiomyopathy, and dilated cardiomyopathy. And have established that it can be used as a surrogate marker of myocardial calcium uptake and handling. So we were very interested to see whether or not patients with acute Takotsubo syndrome have got a myocardial calcium dysfunction and more importantly whether or not this translates into long-term dysfunction and perhaps could explain their symptoms and worse prognosis in long-term. Dr. Greg Hundley: Trisha, manganese MRI. Now, we hear about gadolinium MRI, how is manganese different? You mentioned it's a nice marker for calcium handling. Is this widely used clinically? What kind of contrast does it provide? Dr. Trisha Singh: So manganese was actually one of the first contrast agents to be used with magnetic resonance imaging. It kind of came about in the 1970s and 1980s. And previous animal models have looked at how it is essentially an intracellular contrast agent. And what I mean by that is manganese is a calcium analog and therefore, in cells where they are viable and there's intact cell function, they will be taken up through a voltage gated calcium channels. So, for example, in the heart. So the theory is that manganese, when you've got normal viability, manganese is taken up into the myocardium via voltage gate calcium channels. And several studies have shown that if you then have disease myocardium, these tissues do not take up the manganese as normal tissue would. And the main difference between manganese and gadolinium is they are both paramagnetic, which is why they're helpful and useful in MRI. But gadolinium, as a compound, is too big and it cannot cross an intact cell membrane and therefore, gadolinium is more extracellular. And as, we know, accumulates in tissues where there is increased edema, or water content. So gadolinium, for all intents and purposes, is incredibly useful contrast agent, certainly what we use predominantly at the moment in clinical practice, but it is extracellular. So the theory behind manganese is that it is an intracellular contrast agent as opposed to gadolinium. And where gadolinium accumulates in disease tissue, manganese accumulates in viable tissue. So they behave almost kind of in contrast to each other. And currently, manganese is not used in clinical practice. I think the only clinical compound contrast agent utilizing manganese was mangafodipir, otherwise known as Teslascan, which I believe came off the market in 2012 and that was predominantly used for imaging liver metastasis. Dr. Greg Hundley: Well Trisha, thank you for clarifying for us the difference between manganese, the intracellular contrast agent, and gadolinium, the extracellular contrast agent, that's so widely used clinically. Well, with that description, can you describe for us now, your study population and your study design? Dr. Trisha Singh: Perfect. So the study population was we aimed to recruit 20 patients with acute Takotsubo syndrome. The diagnosis of Takotsubo syndrome was based on a clinical diagnosis, so all our patients underwent a baseline echocardiography and invasive coronary angiography. Now, for us, the coronary angiography was quite important because we wanted to ensure we ruled out anyone with an acute myocardial infarction, which can often be tricky in this cohort of patients. So after recruiting 20 patients during the acute phase of Takotsubo, they all underwent a baseline gadolinium enhanced MRI scan followed by a manganese enhanced MRI scan. And these were done at least 48 hours a part. And then about three months roughly after the acute index, they were all invited to participate in a second manganese enhanced MRI scan. Dr. Greg Hundley: Very good. So two exams separated longitudinally over time. What were your study results? Dr. Trisha Singh: Our results demonstrated that during the acute phase as one would expect, patients had a degree of left ventricular dysfunction. The majority of our patients had afibrillar Takotsubo, so had afibrillar ballooning with preservation of the basal segments. With this, we also noted that in the areas that were affected by Takotsubo, so kind of the mid ventricular wall and the apex that all patients had significantly elevated native T1 and associated T2 as well. And as we expected there was reduced uptake of manganese and therefore kind of reduced calcium uptake in the myocardium in the area affected by Takotsubo syndrome. Interesting, what we also noticed was that all these patients had significantly elevated LV mass, which has been described in previous Takotsubo papers, certainly by Professor Dawson. And when you measured the left ventricular wall thickness, the LV wall thickness is elevated in the affected and actually not even in the non-affected areas, which I suspect explains why in the acute phase people almost doubles up which kind I guess fit with kind of acute myocardial edema and intense water content. And then, three months later when these patients returned for their follow-up scan, a lot of the acute changes had resolved. So native T2 values had improved and gone back to baseline. Native T1 and post contrast T1 values had remained elevated compared to the control population. And what we found was that manganese uptake, though it had improved, it still remained abnormal and reduced compared to the control population, which is a finding that we weren't expecting to find. Dr. Greg Hundley: Very interesting. So acutely we've got extracellular water there, elevation of myocardial T2, and also impaired manganese uptake. So intracellular abnormalities with calcium handling. Then later, so three months later, we have restoration of myocardial T2 so the extra water content is absent, but we have impaired manganese uptake indicating an abnormality with calcium handling. So how do we put this all together mechanistically? What does this tell us about the pathophysiology of Takotsubo syndrome? Dr. Trisha Singh: For one thing, I think we can say that there is, as described before, there is obviously intense myocardial edema present in patients with acute Takotsubo. And I think the significant elevation in T2 and LV mass kind of all fits together. Actually interestingly, as native T2 improves in their follow-up scans, the LV mass actually all return back to normal baseline. So I think the acute edema does resolve. And as you said, interestingly, despite all of these patients, their LV function completely recover. And despite that their myocardial calcium uptake, or handling remain normal. And I think that's not been demonstrated before. And I think it just points to that there is obviously, still something going on in the myocardium and it's not behaving completely normally despite completely normal kind of gross LV function. And potentially, this might point in the direction of why these patients have ongoing symptoms. So, certainly, from our observational cohort group, about 70% of patients had ongoing symptoms and this was predominantly breathlessness and palpitations. And potentially, might be related to why patients have worse outcomes compared to the general population. Dr. Greg Hundley: Very nice. And Trisha, can you describe, was there a therapeutic intervention between the acute and then the three month later measurements? Were these patients administered any type of medical therapy and were there differences in what those therapies may have been between different patients in your study? Dr. Trisha Singh: So predominantly, most of the patient population that were started on some combination of heart treatment due to the baseline LV dysfunction. And this kind of was a combination of most of them were on Ramipril, a few of them were also on spironolactone or eplerenone. And then, every single one was on furosemide. And interestingly, I mean I appreciate, I think the population group was quite small, so it's very difficult to compare those that were on kind of full heart failure treatment versus those who were just on beta blocker and ramipril therapy. But even in that cohort there was a split of about, I think predominantly, I think 17, 16 patients were on kind just beta blockers and ramipril as opposed to beta blocker, ramipril, spironolactone. And there was no difference kind of in the recovery in manganese uptake in that cohort. But, again, the numbers are quite small, so I think it's difficult to extrapolate any kind of true meaning in that. Of course, we know there's a lack of randomized control trial data looking at how to best treat patients with acute Takotsubo syndrome and certainly, what treatment may prevent these patients from having a recurrence of Takotsubo. And I know some of the TACA registry data has looked at actually despite the fact patients of being on beta blocker, or ramipril therapy, they still go having recurrence of Takotsubo and certainly of our cohort, one of our patients went on having a recurrent episode of Takotsubo within a year of her index event and she was on aspirin, beta blocker, spironolactone as well. Dr. Greg Hundley: Very nice. And then lastly, when you made these measurements looking at the manganese uptake or lack thereof, were these in the regions of myocardium where you mentioned many had apical LV wall motion abnormalities, were they in those regions or did you also measure regions remote to where the wall motion abnormality occurred? Dr. Trisha Singh: Of course. So we took measurements in the affected regions of the heart that kind of demonstrated spironolactone syndrome. And we also took measurements in kind of, so to speak, the remote segments of the heart. Now, for the remote segments of the heart, we could only measure native T1 and post contrast T1 at 30 minutes and to measure manganese uptake well, unfortunately, what we have to do is take a measurement over time, so we'd do every two and a half minutes for 30 minutes after the manganese contrast. So we weren't able to calculate manganese uptake in the remote regions. But what we could do was measure the native T1 in the remote region, and then the post contrast T1 and see how it differed with the region of interest in the affected portion of the heart, so to speak. Dr. Greg Hundley: Very good. Well, Trisha, with this really exciting research and very nice methodology, what do you see as the next study to be performed in patients with Takotsubo? Dr. Trisha Singh: So I think, in terms of manganese enhanced imaging, I think it'd be really interesting to re-scan these patients at one year or at two years. And the question there is whether or not their manganese uptake ever recovers really. I know we previously talked about this and thought about whether or not these patients who go onto developing Takotsubo syndrome might actually have a kind of an underlying cardiomyopathy that puts them at risk of developing Takotsubo with stress. So it'd be interesting to see whether or not actually their calcium uptake ever recovers in the long-term, or whether actually they have more of a chronic heart failure type like picture. And I think another area of interest would be to see potentially using manganese imaging as a noninvasive measure of kind of myocardial calcium activity and to see whether or there's any changes with therapy over the course of months to years or so. Dr. Greg Hundley: Very nice. Well listeners, we want to thank Dr. Trisha Singh from University of Edinburgh in Edinburgh, Scotland for bringing us this really interesting article in patients with Takotsubo syndrome demonstrating that there is a marked perturbation of myocardial manganese uptake, which is most evident in the acute phase of Takotsubo presentation, but also persists for at least three months despite apparent restoration of normal left ventricular ejection fraction and resolution of myocardial edema. All of this suggesting that abnormal myocardial calcium handling may be implicated in the pathophysiology of Takotsubo syndrome. Well, on behalf of Carolyn and myself, we want to wish you a great week. And we will catch you next week on the run. This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ajjournals.org.

Keith and Angie Nichols, owners of Tier 1 Health and Wellness, join Rip to discuss hormone optimization for women. 00:38 Today's guests 02:14 Women's health initiative/bio-identical 15:24 T1's approach to women 24:36 Low hormones in young women and the effects of exercise 32:07 The older demographic/thyroid and testosterone 35:18 Big Pharma 43:29 Hormones prevent disease 51:29 Type 2 diabetes and modern medicine 55:30 Do your research 1:03:21 Expectations

Are the shoes HeeSang has to fill simply too large? Can we safely judge anyone from T1? Yiska and Volamel are joined Paul "Paulsible" Morrison and Hamzah "lafon" Mostafa to tackle Overwatch Contenders: Korea and the strength of it's graduating class ahead of the Pacific Showdown. 00:00:00 - Introduction 00:03:39 - O2 Blast a T2 dynasty? 00:10:36 - Looking at other KR contender teams 00:15:13 - How did the meta play out over the tournament? 00:21:12 - Sin Prisa shows strength. Are Ade & TOPDRAGON OWL-worthy? Supports good? 00:29:38 - HeeSang following in Proper's footsteps? Are OW2 teams built around a tank? 00:37:31 - Max potential? 00:49:13 - Can an O2 support bring Bliss to an OWL team? Telling a Babel story 00:55:33 - Keep an eye on these contenders... 01:06:33 - Lightning round: Best of KR Run it back 01:11:14 - How strong is this rookie class? 01:14:52 - Pacific Showdown storylines. Last minute showing for OWL FA signings? 01:29:06 - Support Tier 2! Shout outs & closing

It's a truly long journey this one, part 4 of 4 in fact. I am going to give you the time codes below so if you don't want spoilers then, please, avert your eyes.You can now support A Year in Horror via the Patreon.Theme Music by Max Newton& Lucy Foster.Email the podcast at ayearinhorror@gmail.comDon't bother following the podcast on Facebook. But feel free to...Follow me on Twitter.Follow me on Instagram.Follow me on Letterboxd.Below are the timecodes for all the different segments and my guest links. Feel free to let me know where you think I got it wrong or right and of course stay safe out there & I'll see you next month.0.33 - Inside (2007) w/ Miranda  Corcoran51.08 - Calvaire aka The Ordeal (2004) w/ Amber. T1.22.48 - Gremlins1.32.51 - Outro

Today we explore how technology is making us lonely, how a new pair of glasses may be expanding your idea of a computer screen, and how hitting the snooze button too many times could ruin your sleep hygiene. Techno-Lonely  “Cultivate Deeper Connections Using the Science of Friendship” BY Ryan Jenkinshttps://www.psychologytoday.com/us/blog/the-case-connection/202209/cultivate-deeper-connections-using-the-science-friendship“Teens around the world are lonelier than a decade ago. The reason may be smartphones” by Tara Bahrampourhttps://www.washingtonpost.com/local/social-issues/teens-loneliness-smart-phones/2021/07/20/cde8c866-e84e-11eb-8950-d73b3e93ff7f_story.htmlTV Glasses  “Lenovo's New Glasses Project A Computer Display Inches From Your Eyes” by Daniel Gyllhemhttps://vigourtimes.com/lenovos-new-glasses-project-a-computer-display-inches-from-your-eyes/“The Lenovo Glasses T1 are a monitor you wear on your face” by Joseph Foleyhttps://www.creativebloq.com/news/lenovo-glasses-t1“Lenovo Glasses T1 unveiled: Take a private big screen experience anywhere” by Darragh Murphyhttps://www.laptopmag.com/news/lenovo-glasses-T1-wearable-displaySnooze Button“Hitting the snooze button? You're far from alone, study shows” by UNIVERSITY OF NOTRE DAMEhttps://www.eurekalert.org/news-releases/968205“Snoozing: an examination of a common method of waking” by Stephen M Mattingly et al.https://academic.oup.com/sleep/article/45/10/zsac184/6661272?login=falseFollow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/techno-lonely-tv-glasses-snooze-button

Inside the Eagle Buzz and Neil knew every second was crucial. The T1 time was only 2 minutes so They hastily ran down through their checklists, preparing as though they were going to lift off within the two-minute window. Homepage with pictures

Last week Bill and I were getting geared up for El Tour de Tucson and Ironman Arizona. Today we are going to give a first-hand report on the pro races at Ironman Arizona and do a recap of El Tour de Tucson.   Show Sponsor: UCAN Generation UCAN has a full line of nutrition products to fuel your sport. UCAN uses SuperStarch instead of simple sugars and stimulants to fuel athletes.  UCAN keeps blood sugar steady compared to the energy spikes and crashes of sugar-based products. UCAN also has hydration products focused on giving you the sodium you need when hydrating, including several clean and light flavors. Steady energy equals sustained performance and a faster finish line!   Use UCAN in your training and racing to fuel the healthy way, finish stronger and recover more quickly!  Use the code 303UCAN for 20% off at ucan.co/discount/303UCAN/ or ucan.co   In Today's Show Feature Discussion IM Race Mistakes and How to Avoid Them Endurance News Ironman Arizona Race Report El Tour de Tucson Recap What's new in the 303 How to Prepare Your Bike to Travel   Feature Discussion: IM Race Mistakes & How to Avoid Them Swim DNF: At IMAZ Sunday, approximately 150 athletes DNFd during the swim. The most common cause seemed to be hypothermia or simply being too uncomfortable in cold water to push through. The water temperature was a cool 60.8 degrees (mandatory wetsuit) and I admit that's approaching my limit for comfort.   Tips to Avoid Swim DNF: Be a good swimmer. If you are swimming the Ironman distance you should be swimming at least 10K per week and preferably 15-20K. Your longest swim should be around 5K (longer than the 4.2K of IM). Cold water exposure in the two weeks leading up to the race. This can be ice baths at home or properly supported cold open water with or without wetsuit as appropriate to be exposed to very cold water. Have a good fitting long-sleeve wetsuit with a 5mm or thermal jersey Neoprene cap that fits snugly but doesn't constrict airway (optional double cap) Booties allowed at 65 degrees or colder Vaseline for your face   Bike: The two issues I observed this weekend were mounting and mechanical. Since this was Ironman and most people have their shoes on coming out of the changing tent, not to mention the soft grass surface of the transition area, most do not have the flying mount problem where you can't get your feet in the already clipped in shoes. Most of the near collisions were due to athletes still feeling wobbles from the swim.   One guy had his chain get caught I his rear derailer and he nearly made it worse by trying to ride on it.   Another had a flat the moment he rode out of T1. He had replaced his perfectly fine tubes with brand new ones the day before the race and apparently pinch flatted them. Billy and I helped him fix his flat. Shame.   Tips to Avoid a Bike Mount Disaster: Practice mounts and dismounts Practice change tubes Shake out the bike setup at bike check in If when an issue arises, take a deep breath and slow down   Run: Chaffing - avoidable by using anti chaffing products, testing what you will be wearing on race day during race rehearsals and changing into clean and dry run gear in T2. Dehydration - having practiced your nutrition several times before showing up on race day   News Sponsor Buddy Insurance: Buddy Insurance gives you peace of mind to enjoy your training and racing to the fullest. Buddy's mission is simple, to help people fearlessly enjoy an active and outdoor lifestyle.    Get on-demand accident insurance just in case the unexpected happens. Buddy ensures you have cash for bills fast.  Go to buddyinsurance.com and create an account.  There's no commitment or charge to create one.  Once you have an account created, it's a snap to open your phone and in a couple clicks have coverage for the day.  Check it out!   Endurance News: El Tour de Tucson and Its Dual Personality in the Desert By Bill Plock   November 22, 2022, Tucson: El Tour de Tucson circled the fragile ecosystems surrounding Tucson where Saguaro cacti come to life, thirsty rivers cut the desert, and dreamers come to dream. For thousands of years, people have thrived in this at-first-glance difficult environment. Its dry and hot reputation, while well deserved in summer hibernates in November and offers the perfect weather to ride or race.  It's this dual purpose that gives this tour a dual personality and makes it unique.   Top racers from around the country (the world really) converge in the desert to compete. Riders can qualify for Platinum status to give them a more favorable starting position and a better shot at winning Tissot watches—no monetary prizes.  Riders choose 32, 63, or 102 miles. Said ride director TJ Juskiewicz, about 500 race and the other 7,000 enjoy a well-supported tour.   The logistics of closing roads and controlling intersections for 7,500 riders to ride or race so many miles during most of the day in a big city is incredible. The winner in the 102-mile race was able to average almost 27 mph thanks to top-notch police support. I took about twice as long and received the same support.   I chose to chat as I do, meet some folks and not bonk on undertrained legs and lungs! I made it in part thanks to my podcast partner and close friend, Rich Soares who pulled me more than I pulled him, by a lot! This tour showcased so many personal missions. Whether it was the couple recently married on their honeymoon ride. Or 7-year-old Ariana who rode all 102 miles in about seven and half hours and set a record as the youngest known person to ride a century. Or, Timothy from the Pueblo Road Warrior team (supported by We Ride 4) rocked the 102 miles in his tennis shoes and smiled the whole way.   The vibe oozes a recipe of seriousness, fun, and gratefulness. The contrast of colorful cyclists streaming through the desert, pecan farms, airplane graveyards, and adobe buildings on sleepy streets made the time pass fast. Aid stations all featured friendly bike valets to hold your bike. Kids from the Optimist club or the Boy Scouts or many other local groups smiled big and made us feel very welcomed. Said Rich Soares, “The volunteers were great ambassadors of Tucson and the friendly bike valets were a nice touch and surprise”   That feeling of gratefulness is not an accident. Said Juskiewicz, “We gave away 550 free bikes to kids and our 50+ non-profit partners raised over $5,000,000 for their charities through the  El Tour partnership.”   Coloradans were all over the place. Executive Director of Team Evergreen, Jen Barbour won her age group, and Pete Piccolo, Executive Director of Bicycle Colorado was 22nd overall in a very competitive field that included Primal Ambassador and Tour de France star Jens Voigt who finished 53rd. Other ex-pro's like George Hincapie, Bob Roll, and Christian VandeVelde joined in the fun and said Juskiewicz, “having the rock star pros there was something that took this year over the top.”   Maybe this tour reflects the native Saguaro cactus more than we know. It takes 75 years for Saguaros to grow “arms” to help for better reproduction and continue to flourish and spread more seeds. They stand tall in the desert and have supported human life for thousands of years.  Less than one in a million seeds germinate for this defining plant only found in this area.   As this tour ages and grows, it attracts more and more cyclists and helps more and more people. Its arms are dreams and a safe harbor for so many charities raising money to spread more seeds and help humanity. As a late-season destination, a challenging well-run ride, a trip to Tucson makes for a nice warm-up to enjoy Thanksgiving week and reflect on what's important.   IRONMAN Arizona 2022 - Pro Race, Age Group Kona Slots, Observations There were reasons to be excited about this pro race. On the women's side you had Sarah True, Skye Moench, Lauren Brandon, Melanie McQuade and others. On the men's side you had 70.3 World Champs 2nd place Ben Kanute taking his first swipe at the full distance. Familiar names like Sam Long, Matt Hansen, Joe Skipper and Bart Aernouts.   Pro Women: Lauren Brandon, Sarah True and Skye Moench were 1, 2 and 3 out of the water. Skye would take Sarah's spot at mile 28. By mile 66 Laruen Brandon dropped back to 3rd with Skye leading the way and Sarah just biding her time. Skye entered T2 about 3 minutes before Sara True and Lauren Branden arrived 2 minutes later. About a mile into the run, Sarah True took the front and held that position the rest of the run. By mile 8, Melanie McQuaid moved up to 3rd, but she would fall back to 6th by then finish. At mile 14 they came through and I was giving the pro women splits. Sarah True held on to 1st, Skye Moench held on to 2nd and Daniel Lewis would finish 3rd.   Pro Men: Andrew Hosfall-Turner was first out of the water with Ben Kanute on his heels. By mile 30, Ben Kanute was in control with Joe Skipper in 3rd, Matt Hanson in 5th and Sam Long in 7th. Billy Edwards and I saw them come through and called out splits. At T2 it was Kristian Hogenhaug in first, followed by Joe Skipper in 2nd, Ben Kanute in 3rd, Sam Long in 4th and Matt Hanson in 5th. My mile 5, Matt has passed Sam and swapped positions. By mile 12 Joe Skipper and Hogenhaug swap positions. Hogenhaug blows at mile 23 and it's now the podium of Joe Skipper Matt Hansen and Ben Kanute in that order.   What's New in the 303: Leaving On A Jet Plane: How To Travel With Your Bike Article and photos by: A.V. Schmit   With the major airlines removing the draconian fees associated with flying with a bike, you may be tempted to bring your bike with you on your next vacation. Passengers on American, United and Delta will pay the same amount for a bike as they would for any other piece of checked luggage under 50 pounds — about $30. That's a far cry from the $150 each way to fly with a bike, only a years ago.   International flights typically offer two checked bags per passenger with no additional cost, so the idea of traveling for an international IRONMAN or IM 70.3 is a lot more approachable. And… If you plan on racing, having the bike you trained with is an essential part of being successful.   “Woot, woot, I can travel with my bike,” they thought, until they realized, “Oh wait, I don't know how to pack my bike for travel.”   Fear not, I can show you some pretty simple techniques to keep your “baby” safe on a plane.   If you are my age, I'm sure you remember the 1970's American Tourister luggage commercial with the Gorilla. And if you don't recall, here it is on YouTube:   The point is… baggage handlers typically tend to be a lot less careful than you might want them to be with your bike. So you need to take steps to prepare your bike for travel the best that you can.   For airline travel, there are really two basic categories of luggage to carry a bike — Padded soft case or hard plastic case. Both have their advantages and disadvantages. With a padded soft case, you typically have to disassemble less of the bike, especially on a triathlon bike. But a soft case does not offer as much protection as a rigid case.   With a rigid bike case, your bike has more protection, but more of it needs to be disassembled to fit. A rigid hard case does offer more protection than a padded soft case. In the event of a catastrophic situation, like a very heavy piece of luggage falling from a height or the bike case falling off the luggage carrier, either event will likely damage the bike contained within either type of case.   Sci-Con TSA 3.0 Triathlon Travel Bag " Trico Iron Case Left, Sci-Con Aerocomfort TSA 3.0 Triathlon Travel Bag. Right, Trico Iron Case.   OK, onto packing a bike for travel. In this example I'm packing a Cervelo P5 three in a Sci-Con Aerocomfort 3.0 padded triathlon bag.   Step 1 – Remove the pedals, and wipe the grease off the spindles with a paper towel or shop rag. Don't worry, we are going to pack a bit of bike grease for re-assembly when we get to our destination. I tend not to want to travel with a full tube of grease, rather I like to squirt a small blob into a heavy-duty zip lock bag. It's lighter, and you are less likely to run afoul of any hazardous chemical limits.   Step 2 — Remove bottle cages and other accessories. Wrap them in bubble wrap for protection and storage later in the process. And, while you're at it, remove any CO2  cartridges, as compressed gas of any kind is not allowed on a plane. Be sure to get replacements at your travel destination.   Bottle cages, pedals and rear derailleur ready for removal and padding.   Step 3 — If you don't have access to a bike stand, then it makes the most sense to remove the wheels from the bike and use the alloy cradle of the bag to support the bike for the rest of the procedure. A P5, as well as many tri-bike frames, has horizontal drop outs, so you will need to slide the rear end of the bike into the Frame Defender Armature and then use the quick release at the front to secure the forks.   If your bike uses thru axles, you will need them to secure the bike frame to the armature.   Step 4 — At this point, I like to wrap the frame in closed cell foam to protect the finish from accidental chips or dings. With the popularity of online shopping, you probably have some thin closed cell foam hanging around the house. If not, you might stop by your local bike store to see if they have any leftover foam packing material from in-bound bike shipments. You can also use “bubble wrap,” but I've found it to be less effective than closed-cell foam.   Step 5 — Since the advent of 11-speed drive trains, virtually all road / triathlon groupsets have a “master link” in their chains. A master link is a special link that uses a mechanical connection to connect the chain. With a simple pair of specialized pliers, it's easy to remove the chain and package it in bubble wrap.   While many boxes and bags make chain removal optional. It's my thinking the more you can do to protect the frame from damage, the better. A chain moving around inside a bag or box can really do a number on your bike's paint. Just take it off.   Step 6 — Remove the rear derailleur. On a Shimano Di2 or SRAM AXS, this is a very straightforward procedure. For Di2 you simply unplug the E-Tube wire and use a hex wrench to remove the derailleur. On a SRAM system, simple use a hex wrench and remove the rear derailleur. It is advisable to remove the battery in the case of SRAM AXS as well, prior to placing it in a zip-lock bag and bubble wrapping it.   For Di2, just make sure the shifters and the battery are disconnected to prevent accidental “shifting” during travel from draining your battery.   For a traditional mechanical derailleur, remove the mounting bolt with the appropriate hex wrench, wrap the derailleur in bubble wrap and tuck it in-between the chain stays and secure it. Be careful not to kink the cable housing.   Step 7 — Remove the quick release skewers from the wheels and place them in the pockets on the left and right side of the bag.   If your bike uses disc brakes, it's recommended that you remove them prior to packing the bike. I know, it's a pain, but so is a slightly bent disc that is rubbing as the wheel rotates. Most disc wheels are either 6-bolt or center-lock.   If your wheels are 6-bolt, you will likely need a T25 Torx wrench to remove and reinstall them at your destination. And if it is 6-bolt, you may want to bring a few extra bolts just in case 1 or 2 of the T25 heads get stripped during the process.   If your wheels use center-locks, be sure to pack the tools you will need to get them back on.   Step 8 — After you have removed the pedals, chain, rear derailleur, water bottle cages and accessories. Wrap them carefully in bubble wrap and place them in the storage bag that will be placed under the down tup of the frame and secure the bag. This is also a great place to stow the tools you will need to put the bike back together when you arrive at your destination.   Step 9 — Add additional padding to delicate parts of the bike, including the shifters mounted on the aero extensions.  Insert the wheels into the pockets on the left and right of the bag. Be sure to remove your skewers and wrap them in bubble wrap before you stow them in the bag.   Secure the Velcro and other straps and prepare to close the bag. Before you do, it is a good idea to take some pictures of your packing job so there is no question about how the bike was packed in the event there is an incident during travel.   Step 10 — BONUS — If you use an iPhone, then I would highly recommend you place an Apple AirTag somewhere in the bag. This gives you extra piece of mind that your bike has made it on the plane safely. An AirTag is a blue tooth device that can use the location data of any iPhone it encounters to pinpoint the position of your bike.   Your bike arrives in tact, you've taken the time to put it back together and now it's time to rack it and race the next day.   Video of the week: Skip This Week   Closing: Thanks again for listening in this week.  Please be sure to follow us @303endurance and of course go to iTunes and give us a rating and a comment.  We'd really appreciate it! Stay tuned, train informed, and enjoy the endurance journey!

2022 年 11 月，隸屬台灣職籃 T1 聯盟的桃園雲豹簽下曾 8 次入選 NBA 全明星賽，在 2020 年獲得總冠軍的 NBA 球星「魔獸」—德懷特．霍華德（Dwight Howard）。對於這個震驚台籃圈的決策，T1 聯盟副會長劉奕成說，一切都是從跳脫框架的思維開始。 1️⃣ 如何改變市場對 T1 的看法，做到策略轉型？ 2️⃣ 台灣的人情味是請到霍華德的關鍵？ 3️⃣ 不要去想可不可以，帶著跳脫框架的思維行動，才能打破常規！

這集沒NBA了，直接來個周末分享↓↓↓ (00:32) Bryant泰國糜爛之旅 (30:43) 台北雙層巴士 (33:01) T1雲豹主場真的不行~ (42:28) Nickthereal Realive Concert (45:39) 推歌時間~ 周湯豪 NICKTHEREAL - FUTURE IN YOUR EYES、Emotional Oranges - West Coast Love 小額贊助Link

Gheobhaidh na mílte dalta ar fud na tíre torthaí an Teastas Sóisearaigh inniu. Seo an chéad uair an múnla nua T1 agus T2 bheith dá mheas i gcás na Gaeilge.

🔁Lo de las redes🔁 https://twitter.com/inyustificado https://twitter.com/Esportmaniacos https://www.instagram.com/esportmaniacos/ Programa patrocinado por: 💚NVIDIA GeForce: https://www.nvidia.com/es-es/geforce/ 💙Referido de AMAZON: https://amzn.to/36cVx3g ​Únete al Discord de Esportmaniacos: https://discord.gg/Fa4fX6H 00:00:00 Intro 00:24:00 Baca a KOI 00:43:50 Cambio en la normativa de fichajes de las ERL 00:46:30 Galatasaray abandona el LoL al no poder acceder a Worlds 01:02:00 El reparto de plazas en la nueva EMEA Masters 01:08:05 Attila y Alby a Giants 01:22:00 Faker explora ofertas, ¿se irá de T1? 01:44:50 Cambios en FNC TQ 01:50:00 Hatrixx y Doxy renovados en UCAM

Our special guest will be 36 year veteran from TROY FD Battalion Chief Tom Miter. His sons Justin and Jeremy Miter, are also members of the Troy Fire Department. Prior to being hired as a Firefighter during his high school days Tom was a wheel washer at Station 2 for many years. In 1986 He began working as a firefighter going to E5, M2, M3, and then back to E5. He was promoted to LIEUT 1994 working in T1 and T2. He was promoted to CAPT. June 1998. He left on deployment in the Air national Guard twice in 2002 and 2004 to Iraq. After returning he was promoted to BATT. CHIEF JULY 2015. he just retired in 2022. Tom was a past executive board member of the Troy Uniformed Firefighters Association Local 86. He has been to many memorable jobs over the years, been a teacher of leadership and mentoring skills, and has maybe pissed of a chief or two...maybe my kind of guy ;) ...You don't want to miss this one. You can also Listen to our podcast ...we are on all the players #Troy #GOAT #lovethisjob #givebackmorethanyoutake www.youtube.com/gettinsaltyexperience---Connect with Us---OUR MERCH WEBSITE : https://gettinsaltyapparel.com/INSTAGRAM: https://www.instagram.com/saltydoginc/FACEBOOK: https://www.facebook.com/gettinsaltyapparelTWITTER: https://twitter.com/saltydogapparelSPOTIFY: https://open.spotify.com/show/4QSZ6kGOIXa3YuqHv8m0FuSPREAKER: https://www.spreaker.com/show/gettin-salty-experience-podcastAPPLE PODCAST : https://podcasts.apple.com/us/podcast/gettin-salty-experience-podcast/id1497426893

終於有個像樣的NBA球員來台灣打球了

Sergei Abdulmanov is a desperate traveler, one of the country's best experts in client communications and content marketing, and the owner of a PR agency. Mathematician by education. From 2010 to 2019 Marketing Director of Mosigra. In 2018, Mosigra won the Best Marketing Campaign at the Big Turnover Award and the Best Offline Customer Experience at the CX World Awards. Author of the best business book 2016 (PwC) "Business as a Game" First on Habr (IT resource) in the rating of users by "karma". Now director of client communications at Tutu.ru (Russian travel service No. 1 since 2014), founder of the LOFT PR agency (among clients are Yandex, Sber, CROC, T1, Visa, Rostelecom, SAS, etc.) and several others projects. The main specialization is client communications and content marketing. Typical marketing tasks, "humanization" of the company's image in PR, HR PR-tasks. FIND SERGEI ON SOCIAL MEDIA Facebook | Habr | Telegram ================================ SUPPORT & CONNECT: Support on Patreon: https://www.patreon.com/denofrich Twitter: https://twitter.com/denofrich Facebook: https://www.facebook.com/denofrich YouTube: https://www.youtube.com/denofrich Instagram: https://www.instagram.com/den_of_rich/ Hashtag: #denofrich © Copyright 2022 Den of Rich. All rights reserved.

This week, please join authors Qiang Zhang and Matthew Burrage as well as Senior Associate Editor Victoria Delgado as they discuss the article "Artificial Intelligence for Contrast-free MRI: Scar Assessment in Myocardial Infarction Using Deep Learning-Based Virtual Native Enhancement." Dr. Carolyn Lam: Welcome to Circulation On the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your cohosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Peder Myhre: And I'm Dr. Peder Myhre from University of Akershus University Hospital in Norway. Dr. Carolyn Lam: Peder, today's feature discussion is on AI for contrast-free MRI. Isn't that so cool, using AI to perhaps understand what we could see only with contrast, but now in a contrast-free manner. Now I know that sound a bit confusing, but I hope very, very enticing, because everyone's going to have to wait for a little while before we get to that interesting feature discussion. And for now, let's talk about some of the papers we have in today's issue, shall we? Dr. Peder Myhre: Yes, Carolyn, I can't wait for the feature discussion, but we're going to start with some of the other papers in this week's issue, and we're going to start in the world of preclinical science with a paper looking at human cardiac reprogramming, because Carolyn, direct cardiac reprogramming of fibroblasts into cardiomyocytes has emerged as one of the promising strategies to remuscularize the injured myocardium. Yet it is still insufficient to generate functional induced cardiomyocytes from human fibroblasts using conventional reprogramming cocktails and underlying molecular mechanisms are not really well understood. Transcriptional factors often act in concert and form tightly controlled networks featuring with common targets among different transcriptional factors. Therefore, missing one component during heart development could lead to heart function defects and congenital heart disease. And in this study by corresponding author Yang Zhou from the University of Alabama at Birmingham, the authors perform transcriptomic comparison between human induced cardiomyocytes and functional cardiomyocytes to assess additional factors that govern transcriptional activation of gene programs associated with sarcomere contractility. Dr. Carolyn Lam: Wow. Really nicely explained. Thanks, Peder. So what did they find? Dr. Peder Myhre: So Carolyn, through these computational analysis of transcriptomic data, the authors identified TBX20 as the most under expressed transcription factor in human induced cardiomyocytes compared to endogenous cardiomyocytes. They also demonstrated that TBX20 enhances human cardiac reprogramming and improves contractility and mitochondrial function in the reprogrammed cardiomyocytes. Dr. Carolyn Lam: Nice. Could you summarize the clinical implications, please? Dr. Peder Myhre: Yes. So the clinical implications are that enhancing the efficiency and quality of direct cardiac reprogramming for human fibroblast is a critical step in the clinical translation of this technology, and better understanding of this synergistic regulation of key cardiac transcription factors during reprogramming will provide new insights into the genetic basis in normal and diseased hearts. Well, Carolyn, please tell me about your next paper. Dr. Carolyn Lam: Thanks, and we're moving now to kidney disease. Now end stage renal disease is associated with a high risk of cardiovascular events, but what about mild to moderate kidney dysfunction? Is it causally related to coronary heart disease and stroke? Well, today's authors give us a clue, and it's from corresponding author Dr. Di Angelantonio from University of Cambridge and colleagues who took a very unique combined approach to answer this question. They first conducted observational analyses using individual level data from four huge population based data sources, namely the emerging risk factors collaboration, Epic CVD, Jillion Veteran Program and UK Biobank. Can you imagine this comprised almost 650,000 participants with no history of cardiovascular disease or diabetes at baseline, yielding almost 43,000 and 15,700 incident coronary heart disease and stroke events respectively during a 6.8 million person years of follow up. So huge observational study, which they then followed with a Mendelian randomization analyses using a genetic risk score of 218 variants for GFR and involving participants in Epic CVD Million Veterans Program and the UK Biobank. Dr. Peder Myhre: Wow, Carolyn, this is a topic that I think many of us have really been wondering and thinking about. The mild to moderate kidney dysfunction, what does it really mean? And what a beautiful study to answer this. So what did they find? Dr. Carolyn Lam: First, there was a U-shaped association of creatinine-based GFR with coronary heart disease and stroke with higher risk in participants with GFR values below 60 or more than 105 mills per minute per 1.73 meters squared. Mendelian randomization analyses for coronary heart disease showed an association among participants with GFR below 60, but not for those with GFR above 105. Results were not materially different after adjustment for traditional cardiovascular risk factors and the Mendelian randomization results for stroke were nonsignificant but broadly similar to those for coronary heart disease. So in summary, in people without manifest cardiovascular disease or diabetes, mild to moderate kidney dysfunction is causally related to the risk of coronary heart disease, highlighting the potential value of preventive approaches that preserve and modulate kidney function. Dr. Peder Myhre: Thank you, Carolyn, for such a great summary and an important result from that study. I'm going to now take us back to the world of preclinical science and talk about diabetic cardiomyopathy and exercise. And we both know that patients with diabetes are vulnerable to development of myocardial dysfunction, and that exercise, our favorite thing, for maintaining cardiovascular health, especially in patients with diabetes. And despite a wealth of evidence supporting that cardiometabolic benefits of exercise, the precise exercise responsive signals that confer the beneficial effects of exercise in cardiomyocytes to remain poorly defined. And previous studies have identified fibroblast growth factor 21, FGF21, a peptide hormone with pleiotropic benefits on cardiometabolic hemostasis as an exercise responsive factor. And in this study from Aimin Xu from the University of Hong Kong, the authors investigated a six-week exercise intervention program in FGF21 knockout mice and wild-type litter mates that all had diabetic cardiomyopathy induced by high fat diet and injection of streptozotocin. Dr. Carolyn Lam: Nice. So what did they find? Dr. Peder Myhre: Yeah, the authors found that exercise lowers circulating FGF21 levels, therefore remodeling the heart as an FGF21 sensitive target organ. And the protective effects of exercise against diabetic cardiomyopathy are therefore compromised in mice with deficiency of FGF21. They also identified Sirtuin-3 as an obligor downstream effector on FGF21, preserving mitochondrial integrity and cardiac function. Finally, the authors demonstrated that FGF21 induces Sirtuin-3 expression through AMPK-FOXO3 signaling access. Dr. Carolyn Lam: So could you put that together for us better? So what are the clinical implications? Dr. Peder Myhre: So the clinical implications from this paper is that circulating FGF21 is a potential biomarker for assessment of exercise efficacy in improving cardiac functions. And exercise is a potent FGF21 sensitizer in cardiomyocyte and has the potential to enhance the therapeutic benefits of FGF21 analogs in diabetic cardiomyopathy, and selective activation of FGF21 signal in cardiomyocytes may serve as exercise mimetics and represent a promising targeted intervention for precise management of diabetic cardiomyopathy. Dr. Carolyn Lam: Oh my goodness. That is fascinating. Thank you, Peder. Well let's wrap up with what else there is in today's issue. There's an On My Mind paper by Dr. Weir entitled, “The Emperor's New Clothes: Aren't We Just Treating Grades of Heart Failure with Reduced Ejection Fraction.” Dr. Peder Myhre: And there is a Research Letter by Dr. James Martin from Baylor College of Medicine entitled “Gene Therapy Knockdown of Hippo Signaling Resolves Arrhythmic Events in Pigs after Myocardial Infarction.” Dr. Carolyn Lam: Very nice. Thanks, Peder. So wow, let's go onto a featured discussion on AI for contrast-free MRI and a virtual native enhancement here coming right up. Dr. Peder Myhre: Awesome. Dr. Carolyn Lam: Now we all know that myocardial scar is currently assessed non-invasively using cardiac MRI with late gadolinium enhancement as what we would call the imaging gold standard. Wouldn't it be amazing to have a contrast-free approach, which could provide the same information with many advantages such as a faster or cheaper scan, and without contrast associated problems? Well guess what? We're about to discuss that today in a feature publication in today's issue, and I am so pleased to have the co first authors with us today. They are Dr. Qiang Zhang and Dr. Matthew Burridge, both from University of Oxford, and to discuss it as well, our senior associate editor, Dr. Victoria Delgado from Barcelona. So welcome, everyone. Qiang Zhang, could I start with you and ask you, I understand you're a machine learning expert, which means you're probably smarter than all of us here. Could you maybe explain in simple terms what made you and Dr. Burridge do the study? Dr. Qiang Zhang: First? Thank you so much, Carolyn and Victoria, for the invitation. As you have mentioned, late gadolinium enhancement, or LGE, has been the imaging gold standard in clinical practice for myocardial catheterization including scar assessment for patients with myocardial infarction. However, LGE requires the injection for gadolinium contrast, and this is cautioned in some patient groups and increases the scan time and cost. On the other hand, pre-contrast CMR such as Sydney T1-T2 mapping, a gadolinium-free alternative for myocardial catheterization. But their clinical use has been hindered by confounding factors and a lack of clear interpretation. So with our cross deceptor team at Oxford, we developed an artificial intelligence, virtual native enhancement technique VNE. It can produce a sort of a virtual LGE image but without the need for gadolinium contrast. And we have previously tested it in patients with hypertrophic cardiomyopathy as published in this journal last year. And in this new study together with Matt here, we tested in patients with history of chronic or prior myocardial infarction. Dr. Carolyn Lam: Oh wow. Cool. So audience, you heard it. Instead of LGE, we now have VNE, virtual native enhancement. That's super cool. Thank you. Matt, could I bring you in here? So tell us a little bit more about the population you studied and what you both found. Dr. Matthew Burrage: Yeah, absolutely. And thank you so much for the invitation as well. So as Chang has said, this was a single sensor study that we performed at the University of Oxford and specifically targeting assessing myocardial scar in patients with a history of chronic or prior MI. So we had two sources for our population data. Well, first we used our real world clinical service data from our institution. So we screened 11 years worth of patient data for presence of MI. So patients were included. There was a evidence of a previous MI based on an ischemic pattern of LGE, but we specifically excluded patients who had an acute presentation, or if there were features of acute MI on the CMR scan such as presence of myocardial edema or microvascular obstruction. The reason for this is we wanted to keep this as a clean population to avoid the potential confounding effects of myocardial edema or MVO on native T1 values. And so we also excluded other myocardial pathologies such as underlying cardiomyopathies and infiltrative diseases. A second population dataset came from the OX Army study, which is a single center prospective study of patients presenting with acute MI. And for these patients we used their six month follow up scan to again avoid the confounding effects of edema and pathology. So overall we had a total of 912 patients who have contributed over 4,000 image data sets. The patient characteristics, 81% were male, they had a mean age of 64 years and there were cardiovascular risk factors such as diabetes melitis, hypertension, hypercholesterolemia in 20 to 40% of patients, while just over half had a history of previous revascularization. We also separately applied the VNE technology to a pig model of myocardial infarction, which was thanks to our collaborator, Rohan Domakuma in the US. And so those were scans performed eight to nine weeks after an induced MI in the LAD territory in a series of pigs. And so this gave us the ability to provide a direct comparison between LGE, VNE, and histopathology in this model. Dr. Carolyn Lam: Wow. And results? Dr. Matthew Burrage: So what we found and the key results were firstly that VNE provided significantly better image quality than LGE, and this was on blinded analysis by five independent operators from our test data sets. Secondly, the VNE correlated strongly with LGE in terms of quantifying infarct size and the degree of transmurality, so the extent of the MIs in our test data set. We had pretty good overall accuracy of 84% for VNE in detecting scar compared to LGE with no false positive VNE cases. And finally there was also excellent visuospatial agreement with the histopathology in the pig model of myocardial infarction. So really this, we think, is a technology that provides clinicians with images in a format that firstly they're familiar with, which looks like LGE, provides essentially the same information as LGE, but it can be achieved without the need for any gadolinium contrast agents and can be acquired in a fraction of the time. So it takes less than one second to generate the VNE image. So as we've said before, we feel there's a lot of potential here for this technology to potentially eliminate the need for gadolinium contrast in a significant proportion of CMR scans, reduced scan times and costs, increased clinical throughput and hopefully improve the accessibility of CMR for patients in the near future. Dr. Carolyn Lam: Oh wow. That is tremendous. So first of all, congratulations to both of you. Before I ask Victoria for some thoughts, could I also just check with Qiang Zhang, because all AI algorithms need to be externally validated or surely there's some catch to it, or so-called limitations, or something else you may study. Could you maybe round up by saying is there anything that clinicians should not be applying it to or be aware of some limitations or? Dr. Qiang Zhang: Thank you, Carolyn. So a limitation of this study is that the dataset that is used for developing the models, the majority of them are patients around six month after the acute infarction. So where the myocardial infarction is still evolving, which may include residual edema and microvascular obstruction, and that is difficult to assess using the current VNE model. And also we found it challenging to assess small sub endocardial infarction and actually to address those limitations, we are working on improving the VNE models, training it on even larger data sets and training it on LGE to detect small sub endocardial function. And we will further develop it to detect, for example, acute edema and a microvascular obstruction, and in the meantime develop quality control driven AI models to inform the clinical users of and unreliable results. Dr. Carolyn Lam: Wow, thank you. So Victoria, now I'm dying to hear your thoughts. How do you think this fits in the landscape of all AI imaging now? Dr. Victoria Delgado: I think that it's an excellent development and I congratulate the others for the article and the proof of concept that we can move away from the late enhancement and the use of gadolinium enhancement. I think that this is a major step forward because as Matt said, they are going to decrease very much the time of scanning and the post processing because is automatically done as far as I understand. So even if you can interpret yourself the amount of so-called virtual enhancement, the system gives you a value for that extension of the virtual in non-gadolinium enhancement. So that reduces very much the variability that can be in each observer if that is done automatically. But my question to them is also if that can be influenced by the type of scanner that you use, for example on echocardiography, that's much more my field of interest, it depends very much sometimes how the images are processed of which are the vendors that we have used to acquire the images. Is this a limitation for your software? Can you foresee there some variability or is completely independent? Dr. Qiang Zhang: Thank you, Victoria. So we are aware of actually the difference of the data produced by different scan of vendors and the advantage of AI-driven methods is that it is data driven. So we plan to incorporate dataset from other vendors so that the trend that VNE models can work with like multiple scanner vendors. This actually will be done alongside the ongoing standardization program of T1 mapping in our group, which is the underpinned technology for VNE. And this is led by Professor Stephan Pitchnik and Vanessa Farrera. And we actually hope the VNE technology as AI driven methods could contribute to a solution to the CMO standardization between the scanner vendor. Dr. Victoria Delgado: And another question, if I may follow in this CMR, it has been proposed as a very valuable imaging technique to assess infarct size and to see the efficacy of some therapies to reduce the myocardial infarction size. How do you think that this new methods will impact in future trials and the way we have been interpreting the previous trials, like for example, the one that you use for the validation? Dr. Matthew Burrage: Yeah, thanks Victoria. It's a really, really excellent question. I think there's a lot of potential for the new VNE technology to also become a clinical endpoint in some of these trials in terms of reduction in infarct size, because the information that we get is more or less the same as we get from the LGE. So there's lots of potential that we can, again, use this as a biomarker in trials for looking at reduction in infarct size and reperfusion therapies. But it has the benefit that it can be done quicker and without gadolinium contrast. Dr. Victoria Delgado: This is amazing guideline and really I would have a lot of questions for them as well. And knowing the literature, for example, in the Scenic center in Madrid that they have been scanning the evolution of myocardial infarction from 0.02 weeks to see how this would translate with your technique. That will be amazing to understand how this can be done. Dr. Carolyn Lam: Oh wow, there you go. New research idea right there. Well how about if we end with a very quick question for each of the first authors. So maybe Matt, you could start, I mean is this ready for primetime and clinical use? And if it's not, what needs to be done to get there? In other words, where are you headed as the next step? Dr. Matthew Burrage: So again, thank you, Carolyn, that's a really excellent question and I think the next step before this becomes ready for primetime clinical use is validating this technology really across the spectrum of other myocardial pathologies. So the next work that we are developing this on is in patients with acute myocardial infarction, and then extending this to sort of acute inflammatory conditions like myocarditis, other non-ischemic cardiomyopathies, things like amyloidosis as well. So this will be the next step into rollout and we are looking to track things like VNE burden and how that relates to clinical outcomes, similar to the previous LGE papers have done across different myocardial pathologies, but then ultimately aiming towards clinical rollout within the next few years. Dr. Qiang Zhang: Yeah, I think pretty much what Matt has said, we're going to develop the deep learning methods and test it further on pretty much the whole spectrum of commonly encountered diseases, and then more complex pathologies such as acute pathologies like edema, microvascular obstruction, and then we test on large population study like UK Biobank and other prospective clinical trials. And of course the most importantly is to roll out for real world clinical use. And as Matt said, we are aiming to do this within the next two to five years. Dr. Carolyn Lam: Wow, this is amazing. Both Victoria and I said thank you, congratulations on this landmark piece of work. Thank you for publishing it in circulation. Audience, thank you for joining us today from Greg, Peder, myself. You've been listening to Circulation on the Run, and don't forget to tune in again next week. Dr. Greg Hundley: This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Show Sponsor AnyQuestion - https://link.anyquestion.com/Greg-Bennett   Support the show at https://www.patreon.com/user?u=26936856 "The Greg Bennett Show"     Ben Kanute is one of the most powerful, versatile Triathletes in the world. Winning major titles over the super sprint style of racing, four Escape from Alcatraz Triathlon championships, and twice a silver medalist at the IM 70.3 World Championships, most recently at this year's World Championships in St.George Utah with an epic head-to-head battle with Olympic Champion Kristian Blummenfelt.   Ben was last on the show, on Oct 4th, 2021, where he shared his journey into the sport and his love for his team and family.   Ben Kanute races without fear, leading out of the water almost every time he starts and forces the race to chase him.   It's been a true joy to watch him develop his craft over the years. He has no weaknesses and races with weapons across the board. His momentum is building and he's spearheading the next generation.   In this episode, Ben disects his turnaround from the past 18 months of racing with some tough performances, physically and mentally. Been also discusses his debut Ironman in 2 weeks.   Timestamps 2:12 - Interview starts 7:25 - Ben explains his training schedule going into St George, and then backing it up 2 weeks later with Ironman Arizona. 9:27 - Greg and Ben discuss the deadlines and fees for professional athletes entering events. Yep, pro's have to pay too! 11:23 - Greg & Ben discuss the past 12 months of racing and how some of those lackluster performances affected his mindset. my team are really good at focussing on the positives 29:31 - Ben discusses how important his team has been in helping turn things arouns. Jim Vance, Bobby McGee, Matt Pendola, Courtney (wife), Seth Pepper have all played a significant role in allowing Ben to become free to play and race. you just wanna go out there and take it 33:32 - Ben always takes a race by the horns. He describes the plan and his mindset during his epic battle at St George. From the weeks leading in, to the transitions, to the final run battle with Kristian Blummenfelt. 38:18 - Ben disects the race, starting with the swim. some guys take the gloves out when the gun goes off 41:51 - Moving through T1, Ben explains the first 10-15 miles on the bike and how he focussed on his watts and just hunkered down. "We were in the 340's for most of the first part of the bike". we train to ride at threshold power 46:26 - Starting the run, Ben relaxed and felt he had a really solid shot at the podium. (with no socks!) If you want to beat the Norwegians, you have to take the race to them ... 52:32 - Ben's description of exactly how the run battle with Kristian played out is a fantastic insight into the mindset of a pro athlete. 54:57 - Ben explains how he felt running down to the finish line. 57:05 - Check out Ben's 176 answers on www.anyquestion.com 59:16 - Interview concludes   Links Be sure and check out bennettendurance.com Find Greg on social media: Twitter Greg Bennett Show Instagram The Greg Bennett Show   And check out Ben Kanute at: https://www.instagram.com/benkanute/ http://www.benkanute.com/ https://twitter.com/benkanute/ https://www.youtube.com/watch?v=ZB3MuY8VlYo

Like many kids, Oreos and sugary cereals were a memorable part of Krishna Kaliannan's childhood. But when he was diagnosed with T1 diabetes as a teenager, he was forced to give up mainstream snacks and cereals. Unimpressed with the low-carb alternatives out there, he created Catalina Crunch to provide the masses with options that are both delicious AND nourishing. He joins me on FUELED to talk about the brand's journey, lessons learned along the way, and how they innovate the snacks and cereals that make Catalina Crunch a cult favorite. LINKSCatalina Crunch: www.us.catalinacrunch.com15% off for FUELED listeners at catalinacrunch.com/FUELED - promo code valid until 12/1/2022Pea Protein: Molly's past podcast: https://podcasts.apple.com/jm/podcast/pea-protein-whats-the-scoop/id1459883591?i=1000579601891

Personalized Computational Heart Models to Predict Sudden Death Risk in Hypertrophic Cardiomyopathy Guest: Ryan O'Hara, Ph.D. Hosts: Anthony H. Kashou, M.D. (@anthonykashoumd) Joining us today to discuss Personalized Computational Heart Models to Predict Sudden Death Risk in Hypertrophic Cardiomyopathy is Ryan O'Hara, Ph.D., candidate in biomedical engineer at Johns Hopkins University in Baltimore Maryland. His current research focuses on the electrophysiology of both ischemic and non-ischemic cardiomyopathies. In this episode, we will look at hypertrophic cardiomyopathy in further detail, as well as how personalized computational heart models can be used to improve risk stratification of these patients. Specific topics discussed: What is hypertrophic cardiomyopathy (HCM) and how does it affect the heart? What are the risks? How is sudden cardiac death risk clinically stratified in patients with HCM? What is the typical treatment? What is a computational, or virtual, heart and how can it be used clinically? What benefit do virtual hearts reconstructed with T1 imaging add to improve patient risk stratification in HCM? eLife paper Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. Facebook: MayoCVservices LinkedIn: Mayo Clinic Cardiovascular Services NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

This week Paula surprises us with a new segment called “Pop Quiz with Paula” and then we go right into your questions. Questions about clipping into your shoes in T1, using stationary bikes with power meters at the gym, how pros warm up before a race, and more! To help support the podcasts, and submit your question, head over to http://www.thattriathlonlife.com/podcast

Henley wins in Mexico - Henley, gaming a Pro V1x golf ball and full bag of Titleist equipment, opened the week with consecutive 63's on his way to setting the tournament scoring record at 23 under par. - He made 25 birdies (T1) over the four days in Mexico while playing his first 58 holes bogey-free, getting up and down 15 consecutive times during that stretch. - Henley, 33, led the field in driving accuracy (78.6%) while finishing second in both Scrambling (90.5%) and One Putts (42). Rory Wins CJ Cup 4 Aces Win LIV Team Championship Seamus Power wins in Bermuda Daniel Summerhays back on the Tour (Korn Ferry) Tiger in Hero LIV News/Rumors Reed is giving out lawsuits like Oprah gives away cars New player???? Xander Schaufle Patrick Cantlay Mito Perera Thomas Peiters Matt Kuchar DP World Tour adds cash$$$$$$ DP World Tour announces record purse for 2023 season, introduces new earnings assurance program Russel HenleyRussell Henley's winning WITB: 2022 World Wide Technology Championship at Mayakoba Published 22 hours ago on Nov 6, 2022 By GolfWRX Staff Driver: Titleist TSi3 (10 degrees) Shaft: Project X HZRDUS Smoke Black 70 6.5 TX 3-wood: Titleist TS3 (16.5 degrees) Shaft: Project X HZRDUS Smoke Black 80 TX Hybrid: Titleist TSi2 (21.0 degrees) Shaft: Mitsubishi MMT Hybrid 100 Irons: Titleist T100 (4-9) Shafts: True Temper Dynamic Gold AMT (4-6), True Temper Dynamic Gold Tour Issue S400 (7-9) Wedges: Titleist Vokey Design SM8 (48-10F @47, 50-08F @51, 54-10S, @55, 58-08M @59) Shafts: True Temper Dynamic Gold Tour Issue S400 Putter: Scotty Cameron Special Select Timeless Long Neck tour prototype Ball: Titleist Pro V1x Grips: Golf Pride Tour Velvet How far did the hit it in 1953? https://www.golfdigest.com/story/ben-hogan-sam-snead-driving-distance-peak-golf-digest-study?utm_medium=email&utm_source=110822&utm_campaign=hitlist&utm_content=DM33341&uuid=2e9cf227eda7418b9c1c4625c27deddd

League of Legends World Championship 2022 concluded this past weekend, bringing one of most memorable storylines in League history. It was a South Korean grand finals with DRX and T1, helmed by Deft and Faker respectively. DRX ultimately came out victorious, giving a historic win to Deft, who has been playing in the shadow of Faker for years. To discuss is freelance reporter Mateusz Miter.

Join MonteCristo and Thorin with guest Peter Dun, former head coach of Evil Geniuses, as they discuss the thrilling end of Worlds 2022, the matchup between T1 and DRX, what the win means for Deft's legacy, the differences in coaching between North America and Europe, the problems with mentality among LCS pros, how LCS team owners and management interact with coaches, the possible roster moves in LEC, the strange trade situation with Elyoya, and more.

00:00:00 HLL World Tour Finale BEGINS 00:04:45 Joe Marsh joins HLL 00:14:30 Pablo's take: the games will be decided by supports, but an adc will get MVP 00:21:40 Revan's take: T1's victory will start Keria on the path to GOAT 00:30:40 Ovilee gracefully joins HLL to ask Faker to rap with her 00:35:45 Danx0r's take: crowd diff will help DRX win 00:44:50 Inero joins HLL 00:49:55 Daniel's take: NA will be a top 2 region within the next 5 years 01:01:52 Zane's take: DL coming back to competitive is bad for NA competition 01:12:20 Lourlo joins HLL, says DRX 3-0's T1 01:14:50 Jack B's take: Zeka will mid gap Faker all 4 games of the series 01:22:20 DL analyzes the botlane matchup 01:29:20 numiii's take: LCS should create more content like the East does for fan retention 01:42:10 take: DL returning would save NA 01:53:10 Noor's take: Groups is the problem with the format, not single elim

Last week brought exciting racing at the IRONMAN 70.3 World Championship in St. George UT with commanding wins by Taylor Knibb and Kristian Blummenfelt. Taylor, Kristian and other big names from last weekend are off to Bermuda for the World Triathlon Championship Series. Show Sponsor: UCAN Generation UCAN has a full line of nutrition products to fuel your sport. UCAN uses SuperStarch instead of simple sugars and stimulants to fuel athletes. UCAN keeps blood sugar steady compared to the energy spikes and crashes of sugar-based products. UCAN also has hydration products focused on giving you the sodium you need when hydrating, including several clean and light flavors. Steady energy equals sustained performance and a faster finish line! Use UCAN in your training and racing to fuel the healthy way, finish stronger and recover more quickly! Use the code 303UCAN for 20% off at ucan.co/discount/303UCAN/ or ucan.co In Today's Show • Feature ○ World Triathlon Series Championship in Bermuda • Endurance News ○ Ironman 70.3 World Championship • What's new in the 303 ○ 2023 Season Race Dates Announced ○ TriDot Pre Season Project ○ Bicycle Colorado - Support bike advocacy and win prizes • Video of the Week ○ Worlds Best Drone Video Extreme Mountain Bike Feature: Bermuda World Triathlon Series 2022 World Triathlon Championship Series Bermuda 2022 World Triathlon Championship Series Bermuda marks a return to this beautiful island for a third edition of WTCS Bermuda and the first since 2019. Much has happened on and off the blue carpet since we were last here, not least Bermuda's very own Flora Duffy making history by becoming the first triathlete to win both the Olympic and World titles in the same year, becoming Bermuda's first ever Olympic gold medallist and more recently the first to defend a Commonwealth Games triathlon title. This weekend, we return to the island for the penultimate Championship Series racing of 2022, and elite men's and women's events that have the potential to make a huge impact on the battles to become this year's World Triathlon Champions. The triathlon world's eyes will be fixed on this beautiful corner of the Atlantic and can expect another dose of high-octane entertainment from the world's best athletes. The island will also host a wealth of Age-Group and kids triathlon races, and it is always gratifying to see our sport continuing to grow among so many people at all levels of the sport. It is precisely these weekends that will inspire future generations to take up the magic of swim bike run and that can be the spark behind the fire of the next Flora Duffy. Bermuda has a strong and important history of triathlon and also with the WTCS, having hosted many professional events since 1987, including three WTCS (formerly ITU World Cups) in the 90's where Flora Duffy, Olympic gold medalist and multiple World Champion, watched as a young aspiring triathlete. Age Group - Saturday, November 5th 8am Elite Men - Sunday, November 6th 11am Elite Women - Sunday, November 6th 2pm Temperature in November varies between an average high of 74 degrees to a low of 67 degrees Fahrenheit. The water temperature also comes down to 73 degrees, however, water visibility remains at 100-120 feet. View on Triathlon Live - TriathlonLIVE Start List: Elite Women • 2022 World Triathlon Championship Series Bermuda • World Triathlon Start Num First Name Last Name YOB Country 1 Flora Duffy 1987 BER 2 Beth Potter 1991 GBR 3 Taylor Spivey 1991 USA 4 Laura Lindemann 1996 GER 5 Sophie Coldwell 1995 GBR 6 Anabel Knoll 1996 GER 7 Taylor Knibb 1998 USA 8 Kirsten Kasper 1991 USA 9 Maya Kingma 1995 NED 10 Miriam Casillas García 1992 ESP 11 Summer Rappaport 1991 USA Start List: Elite Men • 2022 World Triathlon Championship Series Bermuda • World Triathlon Start Num First Name Last Name YOB Country 18 Kevin McDowell 1992 USA 26 Matthew Mcelroy 1992 USA 29 Ren Sato 1995 JPN 30 Seth Rider 1997 USA 38 Chase Mcqueen 1998 USA 48 Brent Demarest 1995 USA 49 Gregor Payet 1995 LUX 50 Miguel Tiago Silva 1998 POR 51 Kristian Blummenfelt 1994 NOR 52 Martin Demuth 1995 AUT 53 Kyotaro Yoshikawa 2000 JPN 54 Gustav Iden 1996 NOR 56 Tyler Smith 1998 BER News Sponsor Buddy Insurance: Buddy Insurance gives you peace of mind to enjoy your training and racing to the fullest. Buddy's mission is simple, to help people fearlessly enjoy an active and outdoor lifestyle. Get on-demand accident insurance just in case the unexpected happens. Buddy ensures you have cash for bills fast. Go to buddyinsurance.com and create an account. There's no commitment or charge to create one. Once you have an account created, it's a snap to open your phone and in a couple clicks have coverage for the day. Check it out! Endurance News: Taylor Knibb Powers to Victory at 2022 Ironman 70.3 World Championships It was the Taylor Knibb show at the 2022 Ironman 70.3 World Championship in St. George as the 24 year-old American put on a master class of racing to take her first-ever 70.3 World title. A master class in racing was held in St. George, Utah this morning during the women's pro race at the Ironman 70.3 World Championship. The instructor: 24 year-old Taylor Knibb, who delivered a confident and commanding swim, bike, and run to take the win in 4:03:20. The Swim Lucy Charles-Barclay and Lotte Wilms finish the women's pro swim leg during the 2022 IRONMAN 70.3 World Championship. After much speculation about whether or not the swim would be shortened after a cold front moved through southern Utah on race week, race morning arrived with 63 degree F water temperatures and the full 1.2-mile swim. Naturally, many assumed this would work to the advantage of defending champion Lucy Charles-Barclay, who is known for building a considerable lead in any swim leg she races. But instead of surging to the front as usual, she found she had company: Lotte Wilms of the Netherlands and American Taylor Knibb were on her feet. At the halfway point, Wilms surged to attempt a pass, and Charles-Barclay matched her speed; Knibb held on in the draft, eventually reeling the two back in. The trio powered through to the swim exit, with Charles-Barclay's 23:50 swim split just barely edging out Wilms' 23:51 at the first timing mat; Knibb followed in 23:54. The Bike With air temperatures hovering around 38 degrees F at the start of the bike leg, it was clear the race would belong to the one who could best manage the cold. Clad in gloves and thermal cycling attire, Knibb wasted no time taking charge on the bike leg, moving to the front within the first mile. With an average speed of 28.2 MPH in the first 20 miles, Knibb's lead only grew: one minute at mile 10, 2:30 at mile 20. But Knibb wasn't the only one moving quickly. Duffy also pushed hard in the initial miles of the bike, shooting out of the rolling hills of Sand Hollow with laser-like focus to move into second place by mile 10. Behind her, India Lee (GBR) and Findlay were the only athletes to match Knibb's blistering pace, and they were each rewarded with a Duffy pass and a turn at second place before mile 30. At mile 40, Charles made her move, pushing back into second place with Findlay and Duffy close behind as they entered Snow Canyon. Lawrence, spent from the cold and the early charge, was unable to respond and fell behind. Within the walls of Snow Canyon, Knibb's lead only grew. With almost five minutes on the chase pack, the young American sailed up the notoriously steep climbs; behind her, Findlay, then Duffy, then Charles-Barclay (again) attempted to drop the hammer, but no one was willing to give up the fight. As the three crested Snow Canyon and powered to T2, they were greeted by Knibb, who was already well into the run course. The message was unspoken, but clear: Knibb's impossibly fast 2:14:41 bike split had given her a lead of six minutes and 44 seconds. The Run From the first steps out of T2, it was clear that Knibb saw the run as a mere formality to the win. With a consistent 5:58 min/mile pace, Knibb's lead grew – and grew, and grew. By mile 4, she had more than 7:30 over her closest competition. Though the victory was all but decided, there was still an intense race going on to see who would get boxed out of the podium. Duffy, Findlay, and Charles-Barclay ran as a pack, each daring the others to make a move. At the halfway point, Charles-Barclay began to fall back, and Duffy's form began to show signs of fatigue. Findlay, sensing it was time to make a move, began to slowly pull ahead. Over the course of the next three miles, she was able to put in more than 40 seconds on Duffy and Charles. But an out-and-back section of the course revealed that those two weren't the only competitors Findlay had to worry about – a hard-charging Pallant-Browne was clocking 5:56 min/mile splits in hopes of running her way from ninth place off the bike and onto the final podium. She made easy work of it, overtaking Duffy and Charles in the final mile of the race. In the end, Knibb's 1:21:48 run and 4:03:20 finishing time was more than enough to stamp her name on the history books as the youngest woman to win the title of Ironman 70.3 World Champion. Findlay followed in 4:08:57, and Pallant-Browne rounded out the podium with a run split of 1:17:45 and an overall finishing time of 4:10:45. A Rollercoaster 70.3 World Championship, Kristian Blummenfelt Holds on for the Win A relentlessly close swim, a controversial penalty, and a run battle for the ages - the pro men's race at the 2022 Ironman 70.3 World Championship was a high-stakes, high-drama affair that had viewers on the edge of their seats from the very start to the very finish. A relentlessly close swim, a controversial penalty, and a run battle for the ages – the pro men's race at the 2022 Ironman 70.3 World Championship was a high-stakes, high-drama affair that had viewers on the edge of their seats from the very start to the very finish. The moment of catharsis came in the form of a Kristian Blummenfelt victory in a staggering 3:37:12 on one of the toughest courses on the 70.3 circuit. Men's Race: The Swim With water temperatures at 62 degrees F and air temperatures at 40 degrees F, the theme of the day was the same as the women's race prior: managing the cold conditions of late fall in southern Utah. Aussie Aaron Royle set the pace, with Americans Ben Kanute and Marc Dubrick hot on his heels. Royle emerged from the water first in 22:20, followed by Marc Dubric and Ben Kanute. But what came next was a rare sight in middle-distance racing: In the span of only 20 seconds, a pack of 19 athletes rushed out of the water as if one unit. It was no surprise, then, that T1 was a bit of a circus, with athletes jockeying for position. The pack, which included Denmark's Miki Taagholt and Magnus Ditlev, Norwegians Kristian Blummenfelt and Gustav Iden, Americans Eric Lagerstrom and Jason West, Germans Mikia Noodt and Frederic Funk, and Canadian Brent McMahon, rushed out of transition as quickly as they entered. Two minutes down from the lead, another chase pack formed, this one containing Canadian Jackson Laundry and American Sam Long. In 34th and 40th place, respectively, it was clear that if they wanted a fighting chance at the podium, they were going to have to put in some big work on the bike to catch their competition. The Bike Blummenfelt had no intention of sitting in the pack and watching the race unfold in front of him. He pushed hard from the very start, setting out at a burning pace of 28 mile per hour in the rolling hills out of Sand Hollow. Sam Long, who had ridden his way from 40th to 8th place in the first 20 miles, was the one who took the hit. After getting caught in a tight spot during a pass involving Laundry, Long found himself with a controversial call-out from the referee and a five-minute stand-down in the penalty box. With a gap of 2:25 and an enormous chase pack of 18 athletes close together whizzing past the yellow penalty tent, Long was visibly upset. The pack emerged from Snow Canyon and descended with reckless abandon, barreling toward T2 at 39 miles per hour. Ditlev tucked in tight and tried to get any advantage he could, entering T2 with a bike split of 1:49:59, nine seconds ahead of Blummenfelt and Funk. But that advantage was erased in transition as Blummenfelt moved from bike to run in a seamless 29 seconds while Ditlev floundered for nearly twice that amount of time. In the end, it was Blu who started the run first. Would this mistake cost Ditlev the race? The Run Though Blummenfelt set out at a 5:47 minute-per-mile pace, his lead didn't last long. At mile 2, he had company in the form of Kanute, who was throwing down 5:16 splits. As he passed Blummenfelt, Kanute turned the screws even more, dropping the pace to a staggering 4:55 minutes per mile. But this didn't shake Blummenfelt, who stayed right on his heels and let Kanute drive the pace for the next eight miles. The effort allowed the two to pull away from the rest of the field. At the five-mile point, the pair had build a 40 second lead over Ditlev and more than two minutes on Funk, Noodt, and Taagholt. But bridging the gap to the front was not the priority for the chase pack – instead, it was holding off a hard-charging Laundry, who was making quick work of moving from eighth off the bike to fifth place. Could he run his way into a podium spot? And then, a dramatic twist: At mile six, Iden simply stopped, sat on the curb, and said “No more.” As he removed his race bib and exited the course, the residual fatigue from his Ironman World Championship victory three weeks prior was evident; defending his 70.3 title was simply not in the cards this year. It would be up to his friend and countryman to bring home the win. Blummenfelt stepped up to the challenge. With only three miles to go, he made his move, taking two steps around Kanute and forging ahead. This time, there was no looking over his shoulder – Blummenfelt was laser-focused on the finish line. His stride opened up, and he pulled away, opening up a gap of more than 20 seconds in less than a mile. All the shell-shocked Kanute could do was watch the Norwegian disappear into the horizon. With a half-smile, half-grimace on his face, Blummenfelt thundered to the finish line at a pace of 4:36 minutes per mile. It was only in the final stretch to the finish line that he relaxed, offering waves and high-fives to the crowd on his way to a run split of 1:11:39 and a final finishing time of 3:37:12. Nairo Quintana's Tour de France tramadol disqualification upheld | Cycling Weekly What's New in the 303: Without Limits Races Announced for 2023 Registration is officially open for all 2023 events with special discount pricing through the end of the season. Please also note that all entry fees have increased by $5, our first increase since 2016. As you can imagine, our production costs saw a 22% increase in 2022, but no worries -our goal will always be to keep triathlons affordable for everyone. If you have a volunteer credit from this past season, be sure to cash that in soon for the best possible savings. June 3rd – Colorado Triathlon June 17th – XTERRA Lory Triathlon July 16th – Boulder Peak Triathlon July 23rd – Steamboat Lake Triathlon August 6th - Stagecoach Gravel Triathlon August 20th – Outdoor Divas Triathlon September 16th - Harvest Moon Long Course Triathlon September 24th – Oktoberfest Sprint Triathlon June-August – Stroke & Stride Series BBSC 2023 June 25 - Boulder Sunrise July22 - Tri Boulder August 26 - Boulder Sunset Invitation to TriDot Pre Season Project The Preseason Project® is a triathlon research initiative that helps TriDot quantify and enhance the performance gains that TriDot's Optimized Training™ delivers over training alternatives. Welcome to the 2023 TriDot Preseason Project (PSP) application. Submit this 2-minute app to qualify for 2 FREE months of optimized triathlon training with the TriDot Mark Allen Edition. PSP is an annual R&D initiative that helps triathletes reach their true performance potential through optimized preseason training. It also quantifies the substantial performance gains that TriDot's Optimized Training delivers over training alternatives. You qualify for the FREE training if you meet the following criteria: • Planning an Olympic, Half, or Full triathlon for 2023 season • Train using a device with GPS and/or power • Have not used TriDot in the last 6 months • Not a professional triathlete • Enthusiastic and motivated to get a jump start on your season! * Applications are reviewed and accepted on a first-come basis and must be fully completed to be considered. Register For Free Bicycle Colorado - Support bike advocacy and win prizes Donate Shop Share the Road License Plates Current Issues Education Calendar Our Equity Work Maps & Resources Visit the Blog Visit the Hub Volunteer Action Center Schedule your gift for Colorado Gives Day! A group of bicyclists make their way down a street with a young child leading the way and Bicycle Colorado and Community First Foundation: Colorado Gives Day logos in the bottom right corner. We are just over a month away from Colorado Gives Day—our biggest fundraising day of the year! As a membership-based nonprofit, Bicycle Colorado depends on the generosity of supporters like you to make our work possible. Now until December 6, you can schedule a Colorado Gives Day donation, committing to help us make Colorado a better state for every person who rides or would like to ride a bike. On Colorado Gives Day, you can sit back and relax, knowing you've done your part. We've had some enormous wins this year, like the Colorado Safety Stop, updated “3 Feet to Pass” road signage and the most state funding for eBikes in the country. We can't wait to see what our donors on this Colorado Gives Day will help us achieve next, so we can make Colorado an even better place for bicycling together—schedule your gift now. Take our Bicycle Friendly Driver course Our next virtual Bicycle Friendly Driver course is next Wednesday, November 9! We'll cover laws and safe practices for both drivers and bicyclists, navigating bike infrastructure and avoiding common types of crashes. This webinar is great for all ages and levels of drivers—and bicyclists! Attendees have shared that they benefited from the course and that all road users in Colorado should take it—register to attend for free! Emily's summer research digs into transportation equity This summer, our Transportation Equity Fellow, Emily Maruyama, conducted thorough and meaningful research about how equitable access to transportation in Colorado affects equitable access to healthcare, education and employment, especially in smaller towns and rural areas. She recently presented her findings to interested staff from CDOT and CDPHE, Bicycle Colorado staff and statewide coalition partners working to improve transportation equity. Emily's work is captured in her report, Reconnecting Communities: A Vision for Transportation (coming soon to our blog!). We are thankful Emily was part of our team this summer and are excited to see her excel in future endeavors. Our fall raffle is now open! Take your opportunity to win an Alchemy Ronin Ti or a family package of Cannondale bikes! Your ticket purchase supports bike advocacy and you could win a sweet bike (or a few)—it's a win-win! Tickets are available now until November 21 for the Cannondales, and for the Alchemy, until November 21 or when all 300 tickets are sold. Almost half of the Alchemy tickets have already been purchased, so don't miss out. We are grateful to our friends at Alchemy Bikes and Pedal of Littleton for donating these bikes to us because of their shared belief in better bicycling for people in Colorado. Join the cause and get your tickets now! Just looking to upgrade your current bike? Win a sweet new wheelset from our friends at HUNT Bike Wheels and Without Limits Productions! They're hosting their own raffle benefitting Bicycle Colorado and we're grateful for their generosity. From now until November 29, you can enter to win HUNT's newest 25 or 40 Carbon Gravel Race Wheelset for a $15 ticket that directly supports our work. This weekend: Watched mens pro race riding 4 hours Dropped off bike with Andy Riding with one of my athletes Video of the week: World's Best FPV Drone Shot? (Extreme Mountain Biking)   Closing: Thanks again for listening in this week. Please be sure to follow us @303endurance and of course go to iTunes and give us a rating and a comment. We'd really appreciate it! Stay tuned, train informed, and enjoy the endurance journey!

FINALS ARE HERE! In Divephpria Episode 4, Caedrel, Kobe, and Vedius give an in depth recap of the semifinals, share spicy hot takes, discuss the DRX Cinderella story & what it takes to win a title, and choose their picks for who takes home the hardware. This is a hefty episode, but don't fret. The squad will warm you up with some fun facts, allow you to dive in, and leave you eager to watch the finals! Tune in this Saturday 11/5 for the FINAL matchup as T1 takes on DRX at 8PM ET // 2AM CEST. --- Send in a voice message: https://anchor.fm/the-dive-esports-podcast/message

Join Dr. Amy & Dr. Gene Nicholson, as we discuss the needs of children and families with complex medical needs. He also discusses how he's learned to set clear boundaries and priorities to protect his own mental health. Dr. Nicholson's compassion, energy, and hard-fought lessons bring insight and understanding to his patients & colleagues. Dr. Nicholson, a Kaiser Physician, has a primary care clinic, and a diabetes clinic (for kids w T1 and T2 diabetes), and has been working in a multidisciplinary chronic pain clinic since February 2022.  He has also worked on the wards at Doernbecher Children's Hospital.  He volunteers for Gales Creek Camp since 2011, where he serves as a camp doctor one week every summer.  He has been awarded the “Distinguished Physician Award” by his colleagues within Kaiser Permanente.Gales Creek Camp National Diabetes Camp Registry RESOURCESDr. Amy's Provider NewsletterProvider Lounge MembershipDr. Amy YoutubeFREE DOWNLOADSProvider Lounge Virtual Meeting FreebieStart Creating Boundaries Handout & ScriptGuide To Creating Cultures of Trust At WorkFinding Calm to Prevent OverwhelmDon't Forget! Follow Dr. Amy on LinkedIn, Facebook, and InstagramFor more information visit www.doctoramyllc.com 

Join MonteCristo and Thorin with guest Wolf Schröder, LCK caster, as they discuss the conclusion of the Worlds semi-finals, the incredible upset of DRX over Gen.G, how T1 defeated JDG, the possible pick/ban meta between DRX and T1 in the finals, Zeka as the leader of the MVP race at Worlds, why Faker deserves this week's Big Dick Energy Trophy, and more.

Bobby Julich joins David and Xylon to hear about their respective experiences at the Berlin Marathon and IRONMAN World Championships in Kona. 02:11 – David's post marathon training protocol 03:43 – How bad is post marathon soreness and what impacts it? 06:00 – Bobby's efforts at the Hincapie Gran Fondo 13:20 – Xylon's training since Kona 14:20 – User question regarding the glucose score and drops in long endurance activities at variable pace? What drives glucose up? 21:54 – Intensity vs other causes of drops and relative changes in glucose vs low glucose and feeling poorly 23:18 – Berlin marathon 23:42 – Goals pre-race 24:14 – Days leading into the race and what they entailed 25:38 – Race Day pre-race 26:28 – What warm up do marathoners get to do pre-race 28:45 – What allowed David to pace so well and consistently? What did he focus on? 34:35 – The last few kilometers of a marathon and pacing 36:22 – How do you run a constant pace? 37:33 – What do you use on your watch to pace better? 39:14 – Post race or workout rushes and what drives them? 42:02 – Xylon's marathon of travel to Kona 43:37 – Xylon's training camp at Rocacorba cycling 44:24 – How Xylon approached the daunting task of a non-wetsuit swim 48:24 – When did things get crazy on the island? 49:50 – Bobby arriving on the island 53:26 – Bobby in person rather than on audio 54:01- Bobby's impression of Xylon and his dress sense upon meeting him 57:45 – Bobby's impression of triathlon bikes 60:40 – Bobby's impressions of Ironman athletes, the magic of Mike Reilly's “you are an ironman” and the seed is planted 62:00 – Bobby considering an Ironman 63:12 – Bobby's impression of supershoes and what makes a supershoe? 67:15 – Race morning for Xylon and what it entailed 69:40 – The swim and swim start 71:30 – Xylon admits to never having finished a full ironman before 73:30 – T1 and Bike 75:04 – Xylon has to dismount due to back pain 77:08 – Process focused goals to perform 78:20 – Leaving T1 and Bobby's thoughts on the stress of the mount line 82:30 – T2 and the carnage 83:30 – Planning and taking your time through aid stations and transitions to perform better 85:32 – The run leg 89:25 – Pacing properly at Kona 89:43 – Pro tip for nausea and gut issues 91:10 – Bobby enjoys watching the run and its emotion 92:50 – Bobby considers his Ironman debut 94:44 – Xylon finishes his run 100:30 – Supersapiens surprises Xylono by getting his wife into the finish area 101:20 – Pro tip for post-race nausea 104:00 – Bobby proposes a change to post race procedures for Ironman 104:30 – Bobby and the Supersapiens crew run into two guys from the mean streets of Bergen in a dark parking lot

L'advocat expert en drets dels passatgers Dan Mir

Episode 3 has arrived! As we head into the semifinals, Drakos, Kobe and Caedrel recap Quarterfinals, talk more shop about Meta, breakdown highlight reel worthy gameplay, and get in their feels about what's to come in the Semifinals. The gang even made predictions based on dreams alone…spooky! Tune in this Saturday 10/29 for our first Semifinals match to see T1 vs JD Gaming at 2PM ET // 8PM CEST --- Send in a voice message: https://anchor.fm/the-dive-esports-podcast/message

Join MonteCristo and Thorin with guest Wolf Schröder, LCK caster, and Jakob "YamatoCannon" Mebdi, head coach of Fnatic, as they discuss the wild quarterfinals at Worlds, the struggles of Fnatic during the play-ins and groups, the stylistic match-ups between T1 vs JDG and Gen.G vs DRX, the epic inhibitor respawn in EDG vs DRX, the reasons why this meta is so spectacular, and more.

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics: Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00) Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26) Emerging data with novel agents and strategies for the management of UBC (14:52) Case: A man in his mid 70s with a history of high-grade T1 disease who is not a good candidate for cystectomy (18:57) Case: A man in his early 80s with high-grade T2 MIBC who is not a candidate for cystectomy or neoadjuvant chemotherapy (22:27) Case: A woman in her late 50s with completely resected UBC with a strong preference for bladder-sparing treatment (24:43) CME information and select publications

Joe Marsh is the CEO of T1 Entertainment and Sports, the group behind South Korea's most successful esports team. Prior to running T1, Joe worked at Comcast Spectacor, the owners of the Philadelphia Flyers, and became a part of its initial esports group, who now own the Overwatch League's Philadelphia Fusion, have relaunched gaming TV network G4 and are co-owners of T1, alongside South Korea's SK Telecom. "The issue is the people that had bloated valuations a couple years ago and now they have no revenue to show for it. They can't raise new capital because everyone's taking a down round and that is why you're seeing the esports winter approaching." You can follow Joe and T1 here. Go to https://betterhelp.com/visionaries for 10% off your first month of therapy with BetterHelp and get matched with a therapist who will listen and help. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join MonteCristo and Thorin as they discuss the Worlds 2022 Play-Ins stage, RNG and DRX's current form and potential in groups, the elimination of MAD Lions at the hands of Evil Geniuses, predictions for the Group Stage of the Worlds Main Event, who are the favorites for the title, how DAMWON Kia and T1 may be bolstered by the emerging meta, and more.

In this episode of BackTable Urology, Dr. Aditya Bagrodia discusses retroperitoneal lymph node dissection (RPLND) for early stage testicular cancer with Dr. Clint Cary and Dr. Timothy Masterson from Indiana University School of Medicine. --- CHECK OUT OUR SPONSOR Laurel Road for Doctors https://www.laurelroad.com/healthcare-banking/ --- SHOW NOTES First, the doctors discuss how to approach T1 testicular cancer, which does not show elevated markers or nodal metastases. All the doctors agree that the best approach is just surveillance of the tumor without RPLND, unless there is evidence of somatic transformation. Because some patients have anxiety about just doing surveillance, they assure them that only 10-15% of T1 tumors progress. However, there are different warning signs for different tumor histologies. It is important to get medical oncologists on board quickly in order to have a balanced presentation of treatment options for the patient. The doctors agree that surgeons must counsel patients on the possible complications of RPLND, such as retrograde ejaculation, hernias, and lymphatic leaks, but the probability of these events is low. Next, the doctors discuss whether certain tumor markers can predict the relapse of an early stage testicular cancer. They agree that LDH is not an important marker to check, as it may be falsely elevated. An elevated AFP level can be concerning, but urologists should always put the value into context by comparing to the patient's normal baseline levels and seeing if there is an upward trend. Finally, hCG levels can falsely be elevated by marijuana and hypogonadism. Then, the doctors share their imaging protocol. Standard chest, CT, and pelvic imaging is needed, and Dr. Bagrodia favors chest CT over CXR for better visualization. The doctors also note that more pre-operative imaging immediately before an orchiectomy is not always necessary if the surgeon already has recent imaging. Additionally, the doctors explore approaching T2 testicular cancer, in which there are positive nodes confined to peritoneal nodes. Dr. Masterson and Dr. Cary agree that axial CT imaging is superior. More preoperative factors would be considered such as the focality of the lymph nodes involved, the duration of surveillance time, primary histology of the tumor, and the size of mass. Depending on which lymph nodes are positive (i.e. paraaortic, pelvic. etc.), a surgeon can choose the best RPLND template (modified, unilateral, bilateral). The doctors then explain their intraoperative and postoperative anesthesia protocol. They do not routinely administer DVT prophylaxis before surgery because of the risk of lymphatic leakage. Additionally, they are careful not to disseminate disease by disrupting tumor, which can cause abnormal patterns of metastases Next, the doctors share their post-operative advice for patients. With regards to diets, a lower fat diet will lead to quicker recovery. Ejaculatory function remains normal for patients with unilateral surgery, but should recover within 8-12 months in patients with bilateral surgery. Surgical pathology can determine whether the patient should start adjuvant therapy. For N1 tumors, no adjuvant chemotherapy needed. For N2 tumors, the decision depends on histology and patient factors. Additionally, the doctors explain that extranodal extension does not always mean relapse is inevitable. For this reason, it is important to consider the histology of the tumor. The doctors end the episode by discussing new research on seminoma relapse.

伍德斯托克事件之后已经过去了10年，当年见证了世界与毁灭擦身而过的几个人，他们的生活都已经发生了巨大的变化。如今，一个神秘的电话又将他们重新聚集了起来，一切又都仿佛回到从前，一样的四个人，一样的大众T1，一样的各怀心事的旅途。这一次，一切的线索都将他们引向了一个地方：双泉镇。

之前Roy說如果Rising Star 和攻城獅沒有打進四強，之後乾脆不錄了，現在Rising Star 沒有出線，攻城獅八強出局， 所謂不錄了就像當初聯盟各隊同意Q是本土，校正回歸回來了。   本次錄音我們邀來了在IG的自媒體，籃球伙basketbrostw 來和我們一起錄音，關於這次跨聯盟大賽，大家有什麼觀察？究竟純粹的練兵，還是P寶要瑟瑟發抖的時刻？   除了P.League+兩隊以外，本次T1可以說是大贏家，五隊有三隊打進四強，決賽也是T1內戰，托跨聯盟的福，本次冠軍賽YouTube最高有8500人同時觀看，比賽內容也是相當精彩，究竟是不是該改名T1鍵盤了？   最後當然要聊一下最近的QQ我是誰的事件，錄音的當下，聯盟五隊聯合出了一篇聲明，引起軒然大波，從感性的角度來看，在這個時機點把矛盾擺到檯面合不合適，又從理性的角度看，五隊的聲明是否可行？還有哪些細節和配套需要更改？經過這一次風波，P.League+的形象勢必被衝擊，且看黑人哥該如何化解。   更多主持人蹭熱度與理性討論都在本集節目中，歡迎各大Podcast平台搜尋『小人物上籃- 霹靂鍵盤』收聽！  

Marco presents to physical therapy complaining of diminished grip strength and neck discomfort at rest. Upon examination, the patient has weakened finger DIP flexion and wrist extension compared to the right. The patient also has diminished sensation along the hypothenar eminence. Which of the following conditions is MOST likely present? A. C6 nerve root impingement B. C7 nerve root impingement C. C8 nerve root impingement D. T1 nerve root impingement LINKS MENTIONED: Did you get this question wrong?! If you were stuck between two answers and selected the wrong one, then you need to visit www.NPTEPASS.com, to learn about the #1 solution to STOP getting stuck. Are you looking for a bundle of Coach K's Top MSK Cheatsheets? Look no further: www.nptecheatsheets.com --- Support this podcast: https://anchor.fm/thepthustle/support